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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   INTRODUCTION 
 
Prostatic  disease  is  responsible  for  significant  morbidity  and  mortality 
  in  elderly  men  throughout  the  world. 
Prostate   cancer  and  benign  prostatic  hyperplasia are  the  two  major 
  prostate  diseases  that  increases  with  aging.  The   incidence   of  both the  
 diseases  are  currently showing  a  tendency  to  increase.  In  particular,  increase 
  in  the  incidence  rate  and  the  number  of  death  from prostate  cancer  are  
 noteworthy 
It  is  predicted  that  the  number  of  affected  individual  will  exceed  
 those  of  gastric  cancer,  placing  it  second  to  lung  cancer  by   the  year  
2020.
(53) 
   It is not uncommon to underdiagnose small focus of  prostatic 
adenocarcinoma  or  overdiagnose  benign  lesions  mimicking  cancer.  It  
represents  a  potential  liability  for  pathologist  and  may  cause  unfortunate  
 consequences  for  patients. 
                     
           The  diagnosis  of  prostatic  carcinoma  can  usually  be  made  on 
  morphologic   features  which  include  major  and  minor  criteria,  like  
infitrative  glandular  growth  pattern,  absence  of  basal  cells  and  nuclear  
atypia,   nuclear hyperchromasia,  mitotic  figures  (etc). 
 
 
                 
            However ,  the  diagnosis   of   prostatic  carcinoma  on  routine  biopsies  
 (like  Trucut)  and  TURP  can  be  challenging when  pathologist  are  faced with 
  certain  problems  such as limited  tissue  samples,  small  foci  of  carcinoma  or 
  benign mimickers  of  prostatic  cancer  like  atrophy,  atypical adenomatous  
 hyperplasia,  basal  cell  hyperplasia  (etc).
(64)
  
                   
            Therefore ,  the  application  of immunohistochemistry  to  distinguish 
  prostate  cancer  from  its  benign  mimickers  and  to  confirm  the  diagnosis 
  become   helpful  and  necessary,   especially  in  equivocal  cases.
(64,67)
  
                         
            The   most  commonly  used  basal  cell-specific  markers  in 
  prostatic  gland  are  high  molecular  weight  cytokeratin  (HMWCK)  and  newly  
 described  basal  cell  marker (p63).      HMWCK  shows  cytoplasmic  positivity 
  within  the  basal  cells   whereas  p63  shows  nuclear  positivity  within  the  
 basal  cells.(67)
 
                         
            This  study  mainly  aims  at  evaluating  the  actual  incidence  of 
  differerent  prostatic  lesions  in  this  institution, as  well as  at  evaluating  and  
comparing  the  sensitivity  and  specificity  of  HMWCK  and  p63  in distinguishing  
prostatic  carcinoma  from  benign  prostatic   lesions. 
 
 
                          
 
 
 
 
AIM  OF  THE  STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
                     
                   1.   To   analyse  the  incidence  of  prostatic  lesions  in        
Transurethral   resection  of  prostate,  Trucut  biopsy  in  this  institution  during  
2010-2012. 
        2.        To  subclassify  the  lesions  and  their  prevalence. 
       3.        To  apply   gleason’ s  histological  grading  system  for  prostatic 
 carcinoma 
               4.   To  study  and  compare  the  role  of  P63,HMWCK  in  
distinguishing  prostatic  carcinoma  from  its  benign  lesions  and  its  precursors. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS  AND  METHODS 
 
 
 
 
 
 
 
 
 
 
MATERIALS  AND  METHODS 
 
                This  retrospective study  includes  150  cases  of  prostatic  lesions,  
referred  from Urology  department  of  Thanjavur  Medical  College,  Thanjavur, 
during  the  2  years  period  from  Jan  2010  to  March  2012.   
                         A  detailed  clinical  history  like  age,  duration  of  complaints,  
nature  of  symptoms  and  haematological  investigations  were  done  in  all 
cases.All  types  of  prostatic  specimens  including  TURP  and  Trucut  biopsies  
were  considered. 
                All  the   prostatic  specimens  were  subjected  to  a  careful  and  
detailed  gross  examination. Fixation  was  done  by  neutral  buffered  10%  
formalin   and  paraffin  embedded  tissue  sections  from  these  specimens  were  
used  for microscopic  study.   
                      Sections  were  made  manually  with  histokinette  of  thickness  2 -  4 
micro m.  Staining  was  done  with  routine  haematoxylin  and  eosin  and  every  
slide  was  examined  thoroughly  and  looked  for  the  presence  of  malignancy,  
prostatic  intraepithelial  neoplasia,  metaplasia,  acute  and  chronic  
inflammation  and  other  secondary  changes  associated  with  benign  nodular  
hyperplasia. 
 
 
 
             Immuno histochemistry  with  basal  cell  specific  markers  like  HMWCK  
(34βE12)  and  p63   was  done  for  12  cases  including  nodular  Hyperplasia  of   
prostate,  prostatic  intraepithelial  neoplasia, benign  mimickers  like  basal  cell  
hyperplasia,  atrophy  and  prostatic adenocarcinoma. 
             Statistical  analysis  was  done  to  compare  the  role  of  HMWCK  and  p63   
in  these  cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW  OF  LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
REVIEW  OF  LITERATURE 
 
                  The  human  prostate  gland  is  one  of  the  male  accessory  sex  organ  
which  include  the  prostate,  seminal  vesicle  and  bulbo  urethral  gland( 82,86)   
ANATOMY 
                 It  is  a  pyramidal  fibromuscular  gland  which  surrounds  the  prostatic  
urethra  from  the  bladder  base  to  the  membranous  urethra  and  is  itself  
surrounded  by  a  thin  tough  connective   tissue  capsule. 
                 It  lies  at  a  low  level  in  the  lesser  pubis,  behind  the  inferior  border  
of  the  symphysis  pubis  and  pubic  area  below  the  neck  of  the  urinary  
bladder  and  anterior  to  the  rectal  ampulla  through  which  it  can  be  
palpated.(95) 
                       The  weight  of  normal  adult  prostate  is  20 g  on  an  average. 
Anatomically,  prostate  is  divided  into  five  lobes  anterior,  posterior,  median  
and  two  lateral  lobes.  The  contemporary  classification  of  the  prostate  into  
different  zones  was  based  on  the  work  of  Mc.Neal.(10) 
                  He  divided  prostate  into  peripheral  zone  (PZ),  which  lies  mainly  
posteriorly [ 7o%  of  the  prostate]  and  from  which  most  carcinomas  arise  
and  a  central  zone  (CZ),  which  lies  posterior  to  the  urethral  tumour  and  
 
 
above  the  ejaculatory  ducts.[  25%  of  prostate].  There  is  also  a  periurethral  
and  transitional  zone  (TZ) [5%  of  prostaticvolume]  which  is  the  most  
common  location  of  benign  prostatic  hyperplasia(92) 
             The  capsule  of  the  prostate  is  made  up  of  inner   smooth  muscle  
layer  and  outer  collagen  layer.    The  glandular  elements  are  less  at  the  apex  
with  ill  defined  capsule  which  is  a  mixture  of  striated,smooth  muscle  and  
fibrous connective  tissue.  Hence  the  prostatic  capsule  is  not  a  true  capsule  
but  a  pseudocapsule.(93) 
                The  understanding  of  anatomical  lobes  and  surgical  zones  are  
essential  in  interpretation  of  prostatic  biopsy  specimens  sent  in  transurethral  
resection  of  prostate [TURP]  and  in  trucut  needle  biopsy. 
             The  prostate  is  supplied  by  branches  from  the  inferior  vesical,  
internal  pudental  and  middle  rectal  arteries.  It  drains  into  vesical  and  
internal  illiac  veins. 
             Lymphatics  from  the  prostate  drain  chiefly  into  internal  illiac,  sacral  
and  obturator  nodes.  The  prostate  has  an  abundant  nerve  supply  from  the  
inferior  hypogastric  plexus.(91,95) 
 
 
 
 
HISTOLOGY(91) 
             The  Prostate  is  composed  of  glands  and  stroma  which  has  fibroblast  
and  smooth  muscles.  The  duct  and  glandular  system  is  arranged  in  a  
complete  architectural  pattern.  The  ducts  consist  of  elongated  branching  
tubular  structures  and  end  blindly  in  rounded   acini.  The  glands  are  lined  by  
three  distinct  epithelial  cell  populations. 
                         Secretory 
                         Basal 
                         Neuroendocrine  cell 
                   The  luminal  secretory  cells  are  cuboidal  to  columnar,  have  pale  to  
clear  cytoplasm.  These  stain  positively  with  prostatic  acid  phosphatase,  
prostate  -  specific  antigen  and  other  enzymes.  Non  neoplastic  secretory  cells  
also  may  contain  acid  and  neutral  mucins,  lipofuscin  and  melanin. 
                   Basal  cells  are  peripherally  located  in  the  gland  between  the  
secretory  cells  and  basement  membrane.  These  are  cigar  shaped  with  the  
long  axis  parallel  to  the  basement  membrane.  The  basal  cells  may  have  
either  a  finely  granular,  uniform  distributed  chromatin  pattern  and  show  
cytoplasmic  staining  with  high  molecular  weight  keratin  or  nuclear  reactivity  
for  p63. 
 
 
               These  are  thought  to  represent  the  stem  cell  compartment  within  the  
prostate. Neuroendocrine  cells  are   irregularly  distributed  throughout  the  
ducts  and  acini  and  are  difficult  to  recognize  without  the  use  of  special  
staining  techniques.     
 
HISTOCHEMICAL  FEATURES(10) 
                 Prostatic  secretion  is  commonly  present  atleast  focally,  which  is  
PAS  positive.  Neutral  mucin  may  also  be  seen  in  prostatic  adenocarcinoma.   
                 Acid  mucins   are  not  usually  found  in  normal  or  hyperplastic   
glands  but  are,  found  focally  in  prostatic  adenocarcinoma. 
                 Corpora  amylacea  is  inspissated  secretions  present  within  the  
lumina  of  the  glands.  They  are  seen  in  approximately  25%  of  prostate  
glands  in  men  aged  between  20  -  40  years  and  very  rarely  in  carcinoma.  
They  are  round  laminated  hyaline  eosinophilic   structures  that  may  be  
calcified. 
 
 
 
 
 
 
IMMUNOHISTOCHEMICAL  FEATURES(4,20,37,52,57,58,64,67,80,85,89,96,100) 
               PSA  is  a  diagnostic  and  a  predictive  marker  in  prostatic  carcinoma.  
Since  it  is  present  in  benign  and  malignant  cells  of  the  prostate,it  cannot  
be  regarded  as  a  specific  marker  for  prostatic  carcinoma,  which  include  
antibodies  to    HMWCK ,CK5/6, p63.   These  markers  are  specific  and  are  
commonly  used  for  the  demonstration  of  the  basal  cells.  
              
           Normal  basal  cells  of  the  prostate  will  exhibit  positivity  for  HMWCK  in  
most  of  the  glands. p63  is  a  nuclear  transcription  factor,  which  regulates  
prostatic  glands.The  sensitivity  and  specificity  of  p63  is  comparable  to  
HMWCK  for  the  demonstration  of  basal  cells  of  the  prostate.  Since  it  is  a  
nuclear  marker,  the  detection  of  positively  stained  cells  is  easier  with  p63  
when  compared  to  HMWCK.  
                  
             A recently  discovered  tumor  marker  for  prostate  cancer  AMACR,  P504S, 
AMACR-P  is  being  used  increasingly  in  conjunction  with  H&E  histology  and  
basal  cell  markers  in  work  up  of  prostate  needle  biopsies. 
                       
 
 
 WHO  Classification  of  prostatic  hyperplasia,  Tumours and  Tumour  
like  lesions.(45) 
Epithelial  tumors   
Glandular  neoplasm 
Adenocarcinoma  (acinar) 
     Atrophic 
     Pseudo hyperplastic 
     Foamy 
     Colloid 
     Signet  ring 
     Oncocytic 
     Lymphoepithelioma  -  like 
     Carcinoma  with  spindle  cell  differentiation 
             (carcinosarcoma,  sarcomatoid  carcinoma) 
Prostatic  intraepithelial  neoplasia  (PIN) 
Ductal  adenocarcinoma 
     Cribriform 
     Papillary 
     Solid 
 
 
Urothelial  tumors 
Urothelial  carcinoma 
Squamous  tumors 
 Adenosquamous  carcinoma 
 Squamous  cell  carcinoma 
 Basal  cell  tumors 
 Basal  cell  adenoma 
 Basal  cell  carcinoma 
Neuroendocrine  tumors 
 Endocrine  differentiation  within  adeno  carcinoma   
 Carcinoid  tumor 
  Small  cell  carcinoma 
  Paraganglioma 
  Neuroblastoma 
Prostatic  stromal  tumors 
      Stromal  tumor  of  uncertain  malignant  potential  
      Stromal  sarcoma 
 
 
 
 Mesenchymal  tumors 
     Leiomyosarcoma 
     Rhabdomyosarcoma 
     Chondrosarcoma 
     Angiosarcoma 
     Malignant  fibrous  histiocytoma 
     Malignant  peripheral  nerve  sheath  tumor    
     Hemangioma 
     Chondroma 
     Leiomyoma 
     Grandular  cell  tumor 
     Hemangiopericytoma 
     Solitary fibrous  tumor 
Hematolymphoid  tumors 
     Lymphoma 
     Leukemia 
Miscellaneous  tumors 
     Cystadenoma 
     Nephroblastoma  (Wilms  tumor) 
 
 
     Rhabdoid  tumor 
     Germ  cell  tumors 
     Clear  cell  adenocarcinoma 
     Melanoma 
Metastatic  tumors 
Tumour  like  lesions(17) 
              Benign  prostatic  lesions---   1. Epithelial  
                                                                   2.  stromal 
                  Epithelial ----1.Benign prostatic  hyperplasia 
                                      2.Basal  cell  hyperplasia 
                                      3.Clear cell  cribriform  hyperplasia 
                                      4.Atrophy  
                                      5.Post  atrophic  hyperplasia 
                                      6. sclerosing  adenosis   etc 
                Stromal lesions   
  
 
 
 
 
 
Benign  nodular  hyperplasia 
              The  term  “nodular  hyperplasia”  proposed  by  Moore  is  a  more  exact  
designation  than  the  common  name  BPH.   It  represents  a  nodular  
enlargement  of  gland  caused  by  hyperplasia  of  both  glandular  and  stromal  
components.(61,86)  Nodular  hyperplasia  commonly  affects  the  transition  zone  
and  periurethral  area.(10)   
Epidemiology:(54,55) 
              Nodular  hyperplasia  is  extremely  common  disease  of  the  aging  
population.  It  is  prevalent  in  an  age  group  ranging  from  4th  decade  to  9th  
decade.  
 
Risk  factors(10) 
              The  undisputed  risk  factors  for  nodular  hyperplasia  are  advanced  age  
and  intact  androgen  supply.  These  will  not  occur  in  men  castrated  before  
puberty. The  risk  is  lower  in  patients  with  androgen  resistance  or,  
deficiencies. 
Etiology & pathogenesis(97) 
                   The  etiology  and  pathogenesis  of  nodular  hyperplasia  remain  poorly  
understood . A  number  of  factors,  including  marital  status , socioeconomic  
status,  diseases  such  as  diabetes mellitus,  hypertension  and  cirrhosis,  have  
 
 
been  investigated    and  are  not  thought  to  be  etiologically  related  to  
nodular  hyperplasia.  Testicular  androgen  production  is  necessary  for the  
development  of  nodular  hyperplasia. 
               The  principal  androgenic  hormones  are  testosterone  and  
dihydrotestosterone  (DHT).  DHT  is  the  active  metabolite  of  testosterone  
which  many  believe  is  related  to  the  development  of  nodular  hyperplasia. 
Clinical  features:(10) 
                    Nodular  hyperplasia  of  prostate  interferes  with  the  sphincteric  
function  and  also  causes  urinary  outflow  obstruction  at  the  bladder  neck.  
This leads  to  symtoms  like  increased  frequency, hesitancy, urgency, decreased  
size  of  the  urinary  stream  and  force,  nocturia  and  a sense  of  incomplete  
bladder  emptying. 
Gross appearance(10)                              
                        Grossly,  nodular  hyperplasia  is  composed  of  variable  sized  nodules.  
Cut  surface  of  the  nodules  is  yellow-gray,  soft  to  firm  with  rubbery  
consistency  and  a  bulging  cut  surface.  Weight  of  the  gland  ranges  from  40  
to  400g.  If  there  is  epithelial  predominance,  gland  shows  soft  spongy  
nodules  grossly.  In  case  of  stromal  predominance,  trabeculations  will  be  
seen  in  the  gland  with  no  apparent  nodularity.   
 
 
Microscopic  appearance(84,89,91) 
      Frank’s  classification  of  hyperplastic  nodule 
              The  stromal  (fibrous  or  fibrovascular  nodule) 
              The  fibromuscular  nodule 
              The  muscular  nodule 
              The  fibro adenomatous  nodule 
              The fibromyoadenomatous  nodule 
                   
              The  glands  of  nodular  hyperplasia  are  usually  medium  to  large ,  
sometimes  cystic   and  may  show  architectural  complexity  and  papillary           
infolding.  The  epithelium  usually  has  distinct  double  layer  of  secretory  and  
basal  cells,  but  the  basal  cells  are  not  always  conspicuous.  The  cells  are  
often  thrown  into  papillary  folds  with  some  stratification,  although  the  
nuclei  are  usually  aligned  in  a  single  row. 
 
Secondary  changes  and  other  findings(91) 
                  Sclerosing  adenosis,  cystic  dilatations,  corpora  amylacea,  
calcification,  acute  and  chronic  inflammation  squamous  metaplasia,  
transitional  metaplasia,  infarction  are  at  times  noted. 
 
 
Basal  cell  hyperplasia( 17,18,46,51,59,63,76) 
                      It  is  relatively a  common  lesion  in  hyperplastic  prostates,  being  
examined  in  Turp  specimens  uncommon  in  needle  biopsies.  Occurs  in the  
same  age  group  as  BPH ( mean  74  yrs) . Usually  seen  in  transitionzone  ,  
recently  it  has  been  recognized  that  it  may  also  affect  the  peripheral  zone. 
Classification  of  prostatic  basal  cell  hyperplasia(91)   
                 Complete 
             Incomplete 
             Atypical  basal  cell  hyperplasia 
             Atrophy  associated 
             Adenoid  cystic  like  BCH 
Microscopically(15,16,44) 
              BCH  is  usually  characterized  by  nodular  growth  of  nests,  tubules  and  
cords  filled  with  proliferating,  small  darkly staining  basal  cells,  with  scanty  
cytoplasm,  round  spindly  hyperchromatic  nuclei. 
              May  be  complete  or  incomplete  on  the  basis  of  whether  central  
lumina  are  absent  or  present.  Complete  BCH  is  characterized  by  solid  nests  
of  basal  cells  without  differentiation.(17)   whereas  Incomplete  BCH  often  
 
 
shows  significant  central  glandular  differentiation  with  cuboidal  or  columnar  
secretory  cells. 
            Nucleoli  of  basal  cells  are  usually  indistinct  except  in  atypical  basal  
cell  hyperplasia,  where  it  is  more  prominent  (mean dm  1.96  micro m)  
nucleomegaly,  pleomorphism,  mitosis. 
             BCH  may  also  occur  in  associated  with  atrophy  in  the  setting  of  
antiandrogen  therapy.(46) 
Post atrophic  hyperplasia(16) 
          Post atrophic  hyperplasia  arises  from  the  peripheral  zone  of  the  
prostate.It  consists  of  combination  of  cluster  of  small  acini  which  are  
atrophic  and  those  that  are  lined  by  cells  with  more  clear  and  ambhophilic  
cytoplasm.  The  lobular  arrangement  is  usually  maintained.Budding  of  
neoacini  can  be  seen  which  is  lined  by  cuboidal  cells  with  clear  cytoplasm. 
Clear  cell  cribriform  hyperplasia(46) 
           Occurs  in  transition  zone.  Cells  comprising  the  cribriform  glands  have  
abundant  clear  cytoplasm  and  the  nucleus  is  small  uniform  with  
inconspicuous  nucleoli.  These  cells  are  surrounded  by  basal  cell  layer  in  
many  of  the  glands. 
 
 
 
 Atrophy(6,7,9,16,31,98) 
           It  is  commonly  seen  in  the  peripheral  zone  usually  admixed  with  areas  
of  nodular  prostatic  hyperplasia.  Atrophy  can  also  be  seen  in  central  and  
transition  zones.Radiotherapy  and  antiandrogen  therapy  are  some  of  the  risk  
factors. 
Various  patterns  like  lobular , sclerotic,  cystic  and  linear  patterns  are  
recognized. 
                The  cytological  features  are  common  showing  small,  dark,  shrunken  
cells   having  uniform  nuclei,  and  lacking  nuclear  membrane  irregularity  and  
chromatin  abnormalities ,but  show  high  N/C  ratio. 
Sclerosing  adenosis(15) 
             Incidental  finding  in  TURP  specimens   The  lesion  is  partially  well  
circumscribed  with  minimal  infiltrative  margin  at  the  periphery.  It  is  
composed  of  well  formed  small  glands  admixed  with  a  dense  cellular  
spindle  cell  stroma.   
              The  glands  are  lined by clear cells with small uniform nuclei  with  
occasional    prominent  nucleoli.  Basal  cell  layer  is  identified  in  many  of  
glands  and  shows  striking  myoepithelial  cell differentiation  on  IHC. 
 
 
 
Hyperplasia  of  mesonephric  remnants(23) 
               These  are  composed  of  very  small  glands  with  tubular  dilatation  or  
arranged  in  micropapillary  pattern  with  epithelial  tufting.  The  lining  
epithelium  of  the  glands  are  cuboidal. 
 Verumontanum  mucosal  gland  hyperplasia(40) 
 It  is  characterized  by  uniform  closely  packed  glands  with  corpora  
amylacea.  Basal  cells  are  identified  and  the  nuclear  features  of  malignancy  
is  absent. 
Nephrogenic  adenoma(17,59) 
                This  can  be  rarely  seen  in  prostatic  urethra  which  presents  as  an  
exophytic  lesion,  nodule  or  a  flat  lesion.  
                     Microscopically,  these  are  characterized  by  closely  packed  small  
tubular  structures,  lined  predominantly  by  cuboidal  or  columnar  cells  at  
scanty  occasionally  moderate  to  large  amount  of  eosinophiic  cytoplasm.  The  
nuclei  are   round  and  small  or  pyknotic  and  lack  nucleoli.  Some  have  nuclei  
with  hobnail  appearances. 
Stromal  lesions(17) 
                     Stromal  hyperplasia 
                     Leiomyoma 
 
 
                     Phyllode  -  type  atypical  hyperplasia 
                     Fibroadenoma  like  hyperplasia 
 Stromal  hyperplasia                  
  Benign  stromal  hyperplasia  is  the  most  common  stromal  lesion.  It  is  
characterized  by  a  bland  spindle  cell  proliferation  devoid  of  glandular  
elements,  these  are  arranged in  a  fascicular  or  whorled  pattern. 
Leiomyomatous  nodules: 
             Stromal  nodules  with  prominent  smooth  muscle  differentiation  often  
cellular  with  mild  nuclear  variability. 
Fibroadenoma  like  hyperplasia: 
              Glands  and  cellular  fibrovascular  stroma  are  organized  in  a  fashion  
similar  to  fibroadenoma  of  breast. 
 Phyllodes  -  type  hyperplasia: 
               In  exuberant,  sometimes  myxoid,  stromal  proliferation,  usually  
associated  with  intra  luminal  polypoid  projections  like  phyllodes  tumour  of  
the  breast. 
 
 
 
 
PRE  -  MALIGNANT  LESIONS  OF  PROSTATE(8,11,12,21,26,34,35,42,78,87,90) 
             The  two  proposed  histological  premalignant  lesions  of  prostate  are 
     1.   Prostatic  intraepithelial  neoplasia  (PIN) 
    2.    Atypical  adenomatous  hyperplasia  (AAH). 
 
PROSTATIC INTRAEPITHELIAL NEOPLASIA 
Definition 
               It  is  a  neoplastic  transformation  of  lining  epithelium  of  prostatic  
ducts  and  acini  which  is  confined  within  the  epithelium.
(45) 
                    Bostwick  introduced  the  term  PIN  in  1987  which  replaced  the  terms  
used  earlier  like  duct  acinar  dysplasia,malignant  change  marked  atypia  and  
intraductal  dysplasia.  PIN  is  categorized  in  to  low  and  high  grade  at  present  
as  apposed  to  the  previous  three  grade  system. 
 
PIN  -  1  is  considered  as  low  grade  and  PIN  2  and  PIN  3  are  considered  as  
high  grade. 
 
 
 
 
Prostatic   intraepithelial  neoplasia(10)---Diagnostic  criteria. 
S.NO FEATURES LGPIN HGPIN 
1 Architecture Epithelial Cell 
Crowding and stratification 
with irregular spacing. 
 
 
Similar to low grade PIN  
withmore crowding and 
stratification and shows 
patterns – tufting, 
micropapillary, cribriform 
and flat. 
2 Cytology   
a) Nuclei Enlarged with marked size 
variation. 
Enlarged 
b) Chromatin Normal Increased density and 
clumping. 
c) Nucleoli Rarely prominent. 
 
Occasionally frequently 
large and prominent. 
3 Basal cell layer Intact May show some disruption. 
4 Basement 
membrane 
Intact Intact 
 
 
There  is  much  evidence  supporting  a  preneoplastic  role  of  PIN.  The  
prevalence  of  PIN  increases  with  age,  peaking  in  the  6th  decade  and  
predating  the  onset  of  most  carcinomas  by  more  than  5  years. 
             PIN  is  much  more  common  in  prostates  with  carcinoma  than  in  
benign  glands  and  is  more  often  multifocal,  more  extensive  and  of  high  
grade  in  the  former.  Like  carcinoma,  PIN  is  mainly  identified  in  the  
peripheral  zone  and  is  often  adjacent  to  carcinoma.
(47,97) 
 
LGPIN:(45) 
               In  LGPIN,  secretory  cells  of  the  lining  epithelium  proliferate  and  “pill  
up”   with  irregular  spaces  between  them.  The  nuclei  are  enlarged,  vary  in  
size,  have  normal  or  slightly  increased  chromatin  and  possess  small  or  
inconspicuous  nucleoli.  The  basal  cell  layer  normally  surrounding  secretory  
cells  of  ducts  and  acini  remains  intact.   
 
HGPIN:(93) 
               Characterized  by  cellular  proliferation  within  medium  to  large  glands  
characterized  additionally  by  cytologic  atypia. 
 
 
               Regardless  of  the  architectural  pattern,  nuclear  changes  are  the  
hallmark  of  high  grade  PIN. 
               Nuclei  are  enlarged  with  hyperchromasia  and  irregular  chromatin  
nucleoli  are  large  irregular,  often  multiple  and  may  be  focal  (grade  2  PIN)  
or  more  extensive  (Grade  3  PIN) 
Various  architectural  patterns  of  HGPIN(77) 
            Tufting  :  Nuclei  become  more  piled  up,  resulting  in   undulating  
mounds  of  cells. 
            Micropapillary  pattern :  show  columns  of  atypical  epithelium  that  
typically  lacks  fibrovascular  cores. 
            Cribriform  pattern  :  Consists  of  complex  architectural  pattern  such  
as  Roman  bridge  and  cribriform  formation. 
           Flat  pattern  :  shows  nuclear  atypia  without  significant  architectural  
changes. 
Histologic  variants  :(45) 
             Signet  ring  variant:    HGPIN  with  signet  ring  cells  is  exceedingly  
rare.  Histologically,  cyoplasmic  vacuoles  displace  and  indent  PIN  cell  nuclei.  
The  vacuoles are  mucin- negative by histochemical  staining. 
 
 
            Mucinous  variant  : 
                        It  is  a  rare  variant  exhibiting  mucin  filled  glands  which  flatten  
the  lining  epithelium. 
            Foamy  variant  : 
                  Microscopically,  foamy  PIN  glands  are  large  with  papillary  
infoldings  lined  by  cells  with  bland  nuclei  and  xanthomatous  cytoplasm. 
           Inverted  variant  : 
                        This  is  characterized  by  polarization  of  enlarged  nuclei  towards  
the  lumen  of  glands  with  micropapillary  pattern. 
           Small  cell  neuroendocrine  variant  : 
                        Rare  variant,  where  small neoplastic  cells  are  arranged  like  a  
rosette.  The  small  cells  are  chromogranin  and  synaptophysin  positive  and  
harbour  dense  core  membrane  -  bound  neuro secretory  granules  at  the  
ultra structural  level. 
Clinical  significance  of  PIN  :(36,49) 
                       The  findings  of  low  grade  PIN  should  not  prompt  further  
investigation  and  it  is  not  reproducibly  recognized.  In  contrast,  high  grade  
PIN  is  an  important  diagnosis,  but  should  be  made  with  care.  If  high  -  
 
 
grade  PIN  is  encounted  in  a  needle  biopsy  specimen,  additional  levels  
should  be  considered  to  rule  out  carcinoma.           
                       A  diagnosis  of  high  -  grade  PIN  without  concurrent  carcinoma  
should  prompt  careful  clinical  follow  -  up  and  further  biopsies  especially  if  
the  serum  PSA  is  elevated  or  abnormalities  are  noted  on  rectal  or  
ultrasound  examination. 
 ATYPICAL  ADENOMATOUS  HYPERPLASIA(11,26,40,39) 
                        It  is  one  of  the  most  common  lesions  that  may  be  confused  
with  carcinoma.  Other  terms  for  AAH  are  adenosis,  small  gland  hyperplasia,  
atypical  adenosis  and  small  acinar  atypical  hyperplasia. 
                       It  is  characterized  by  proliferating  small  to  medium  -  sized  acini  
that  usually  form  a  well  -  circumscribed  nodule  but  occasionally  extend  into  
the  adjacent  prostatic  stroma.  This  has  been  identified  in  1.5  -  19.6  %  of  
turp  and  in  up  to  33%  of  radical  prostatectomies. 
Diagnostic  criteria  for  AAH  &difference  between  AAH &  low  grade  
adenocarcinoma.(11,26,39,40) 
 
 
 
 
                                                AT LOW MAGNIFICATION  
AAH LOW GRADE ADENOCA 
Lobular growth Infiltrative/Haphazard 
Small crowded glands admixed with larger 
glands 
May be pure population of small crowded 
glands 
                                              AT HIGH MAGNIFICATION 
AAH LOW GRADE ADENOCA 
 Huge ≥3microm nucleoli absent Occasional huge nucleoli present 
 Small glands share cytological and nuclear 
features with admixed benign glands 
Small glands differ from surrounding 
benign glands 
 Pale to clear cytoplasm May have amphophilic cytoplasm 
 Blue tinged mucinous secretion rare Blue tinged mucinous secretions common 
 Corpora amylacea common Rare 
 Occasional glands with basal cells Basal cells absent 
 Basal cell – specific antikeratin antibodies  
stain basal cells in some glands 
Small glands are not immunoreactive to 
anti keratin antibodies. 
 
 
 
AAH  has been proposed as a precursor of prostatic adenoma in the transitional 
zone.               
                                      CARCINOMA  OF  THE  PROSTATE(25,28,48,53,65,70,71,73,75) 
Prostate  cancer  is  the  most  common  cancer in men  accounting  for  
33%  of  all  malignant  tumors  in  men accounting  for  9%  of  cancer  deaths  the  
third  highest  in  men  after  lung  and  colorectal  cancers. 
            Both  incidence  and  mortality  rate  have  increased  over  the  last  few  
decades  all over  the  world,  even  in  India.
(17) 
            Prostatic  cancer  commonly  occurs  in  the  sixth  to  eighth  decade,  and  
it  is  rare  before  the  age  of  50.  The  incidence  and  mortality  rates  vary  
according  to  geographical  location. The  incidence  is  low  in  the  far east  and  
is  very  high  in  Northern  European and  North  American  populations.(47) 
           The  etiology  and  pathogenesis  of  prostate  cancer  are  poorly  
understood.  Both  genetic  and  epigenetic  factors  have  been  implicated.  There  
is  also  familial  association  in  a  minority  of  cases.  Risk  factors  are  advancing  
age,  race,  heredity  and  hormonal  activity.  The  other  factors  are  viruses,  
cadmium  exposure,  high  fat  diet  vit  A  and  D  deficiency .
(71,91,93) 
 
 
 
Clinical  features  : 
                Prostatic  carcinoma  has  no  specific  presenting  symptoms,  and  is  
usually  clinically  silent  but  locally  extensive tumours  cause  pubic  pain , rectal  
obstruction  or  bleeding. 
                Presenting  symptoms  of  metastatic  disease  include  bone  pain  and  
tenderness,  cord  compression.  On  rare  occasions  prostatic  carcinoma  may  
manifest  as  a  paraneoplastic  syndrome.
(17,24,93) 
Screening  methods  :(70) 
                 Digital  rectal  examination,  measurement  of  serum  PSA,  Transrectal  
ultra  sound  (TRUS).  The  detection  rate  for  DRE  is  about  0.8  -  2.7 %  Most  of  
the  carcinomas are  detected  by  transurethral  resection.
(93,97) 
        In  many  patients  abnormal  PSA  elevation  may  the   first  finding.  A  
PSA  valve  above  4ng/ml  is  considered  abnormal. 
                  On  TRUS,  areas   of  hypoechogenicity  may  be  detected.  But  in  
some  cases,  no  abnormalities  are  seen.  Directed  biopsies  of  abnormal  areas  
can  be  obtained.  If  no  abnormalities  are  detected,  multiple  areas  are  
systematically  biopsied.  Biopsies  are  taken  in  basal  mid  and  apical  portions  
of  the  gland  with  or  without  the  transition  zone,  on  both  sides.
(24,48)
   
 
 
Methods  to  obtain  prostate  tissue  for  detection  of  prostate  
neoplasia: 
Needle  core  biopsy  :(1,60,75) 
              Done  using  18  gauge  needle,  post  biopsy  infection  is  minimal.  
Needle  biopsy  involves  tissue  only  from  peripheral  zone. 
 Transurethral  resection  of  prostate  : 
               In  TURP,  the  tissues  are  removed  mainly  from  periurethral  zone,  
transitional  zone,  anterior  fibromuscular  stroma  and  bladder  neck. 
             If  adenocarcinoma  is  found  in TURP  samples  they  indicate  that  
tumour  has  arisen  from  the  peripheral  zone  which  is  the  common  site  for  
prostatic  adenocarcinoma  and  it  has  invaded  the  transition  zone  which  
means  the  tumour  is  larger  at  an  advanced  stage. . 
Prostatic enucleation [suprapubic  prostatectomy] 
                   In  patient  with  massive  BPH  this  procedure  is  applied.  The  
specimen  usually  consists  exclusively  of  transitional  zone  and  periurethral  
tissue  with  grossly  visible  nodules. 
 
 
 
 
Radical  prostatectomy: 
                  a)Retropubic  prostatectomy  allow  staging,  lymphnode  biopsies  with  
frozen  section  evaluation  prior  to  removal  of  prostate. 
                  b)  perineal  prostatatectomy 
 
Prostatic  carcinomas  can  be  divided  into  two  major  categories 
1) Adenocarcinoma  of  peripheral  ducts  and  acini 
2) Carcinoma  of  large  ducts 
Most  prostatic  carcinomas  arise  in  the  peripheral  zone.  Grossly  the  
tumour  may  be  difficult  to  see,  but  usually  can  be  identified  as  gray  or  
yellowish,  poorly  delineated,  firm  area.  Microscopically,  prostaticadenoca  
exhibit  a  wide  spectrum  of  appearances  ranging  from  anaplastic  tumours  to  
highly  differentiated  neoplasm,  which  will  be very  difficult  to  differentiate  
from  normal  and  benign  glands.
(17,48)
   
 
 
 
 
 
 
Histological  grading 
                 Brode  et  al  is  the  pioneer  who  introduced  the  first  grading  system  
in  1925  in  an  attempt  to  estimate  the  malignant  potential  of  cancer.  It  was  
based  on  degree  of  glandular  differentiation,  cell  morphology,  mitotic  
activity  and  degree  of  invasiveness. 
                   Later  in  1966  it  was  Donald  f  gleason,  Who  created  a  gleason  
grading  system
(27,32,38,62,79)
  which  later recommended  by  a  WHO  consensus  
conference.  He  utilized  glandular  differentiation  and  growth  pattern  in  
relation  to  stroma  to  identify  tumor  grades.  Gleason  grading  system  defines  
five  histological  pattern  or   grades  with  decreasing  differentiation. 
                   In  2005,  international  society  of  urological  pathology  consensus  
conference  on  gleason  grading  of  prostatic  carcinoma  gave  the  modified  
gleason  grading  system. 
 
 
 
 
 
 
 
 
GLEASON’S GRADING SYSTEM : (45,46,79,91,93) 
 
[Adapted from – Benign mimickers of prostatic adeno carcinoma, The Journal of 
modern Pathology (2004),Vol 17 ] 
 
 
This  is  the  most  powerful  prognostic  indicator  of  prostate  carcinoma.
(86) 
        1.   Single  separate,  uniform  glands  closely  packed  with  definite  edges. 
        2. Single separate, less uniform glands loosely packed with irregular        
edges. 
        3A.   Single  separate  variable  glands,  scattered. 
        3B .    Single  separate,  very  small  glands than 3A,  scattered. 
        3C.   Sharply,smooth,  circumscribed  rounded  masses  of   papillary  or  loose  
cribriform  tumor. 
        4A.   Fused  glands,  raggedly  infiltrating 
        4B.  Same  as 4A  with  large  pale  cells  (hypernephroid) 
        5A.  Almost  solid,  rounded  masses,  necrosis  (comedocarcinoma) 
        5B. Anaplastic,  poorlydifferentiated  with  ill  defined  cords &  sheets  of  
cells. 
 WHO  histopathplogical  grading (45) 
       Gx-----Grade  cannot  be  assessed. 
       G1----Well  differentiated  tumour (Gleason  score 2-4) 
       G2------Moderately  differentiated  tumour(Gleason  score  5-6) 
       G3-4---Poorly  differentiated  tumour(Gleason score 7-10) 
 
 
 
 
Gleason  score: 
                  Primary  grade  is  assigned  to  the  dominant  pattern  and  secondary  
to  the  sub  dominant  pattern.  The   two  numeric  grades  are  added  to  obtain  
the  combined  gleason  score.  In  tumors  with  one  pattern  ,  the  number  is  
doubled. 
 
Stout  criteria  for  prostatic  adenocarcinoma(91,93) 
1.   Glandular  pattern  -  small  irregular  glands  without  any  particular  
relation  to  the  adjacent  stroma  or  normal  glands. 
2.   Arrangement  of glandular  epithelium  -  lack  of  basal  cells  in  cancer. 
3.  Cellular  details  -  large,  deeply  staining  prominent  nucleoli. 
 
Criteria  for  diagnosis  of  prostatic  adenocarcinoma(17,47,93) 
  Major  criteria 
       Architectural- Infiltrative  small  glands  or  glands  with  cribriform pattern. 
Basal  cells  are  absent  and  the  glands  are  lined  by  single  cell  layer. 
Features  of  nuclear  atypia  like  nuclear  and  nucleolar  enlargement  are  seen.             
 
 
 
Minor  criteria 
              Intraluminal  crystalloids 
  Intraluminal  wispsy  blue  mucin. 
              Mitotic  figures. 
              Adjacent  high  grade  PIN 
              Amphophilic  cytoplasm 
   Pink  amorphous  secretions. 
Specific  features  of  carcinoma 
             Glomerulations 
  Perineural  invasion 
             Collagenous  micronodules       
Prognostive  factors (84)  
Category  I 
                       Surgical  margins 
Serum  PSA 
                       Pathologic  stage                                                                   
                       Gleason  grade                        
 
 
Category  II 
                    Volume  of  cancer  in  radical  prostatectomy  
          Volume  of  cancer  in  needle  biopsies  histologic  subtype  
         DNA  ploidy 
 
Category  III 
                        Androgen  receptors 
                       Apoptosis 
                       Lymphnode  micro  metastasis 
                       MIB  -  1 
                       Mitotic  figures 
                       Nuclear  chromatin  texture 
                       Nuclear  roundness 
                       PCNA 
                       Perineural  invasion 
                       PSA  derivatives 
 
 
 
 
 
Benign  mimickers  of  prostatic  adenocarcinoma(15,18,23,41,46,51,59,63,76) 
                        In  small  biopsy  specimens,  the  diagnosis  of  prostatic  
adenocarcinoma  is  becoming  difficult  because  of  the  presence  of  numerous  
benign  lesions  which  can  mimic  prostatic  adenocarcinoma  on  
histopathological  examination.  The  mimickers  of  prostatic  carcinoma  can  be  
classified  according  to  their  growth  patterns  so  that  it  can  be  compared  to  
the  patterns  in  gleason’s  gading  system.  There  are  four  major  growth  
pattern  that  can  be  described  in  a  sample  from  prostate.   
1.  Small  gland 
2. Large  gland 
3. Fused  gland 
4. Solid 
 
Benign  mimickers  in  relation  to  major  growth  pattern  of  prostatic  
adenocarcinoma. 
  The  lesions  showing  small  gland  pattern  are 
               Cowper’s  gland 
               Seminal  vesicle 
 
 
               Basal  cell  hyperplasia 
               Nephrogenic  metaplasia 
               Mucinous  metaplasia 
               Atrophy 
               Post  atrophic  hyperplasia 
               Atypical  adenomatous  hyperplasia 
               Verumontanum  mucosal  gland  hyperplasia 
               Sclerosing  adenosis 
               Mesonephric  gland  hyperplasia 
               Benign  nodular  hyperplasia 
Large  gland  pattern  is  seen  in   
              Adenoid  cystic  like  basal  cell  hyperplasia 
              Reactive  atypia 
              Cribriform  hyperplasia 
Fused  gland  pattern  is  seen  with 
              Malakoplakia 
              Paraganglioma 
             Xanthogranulomatous  lesions 
 
 
 
 
Solid  pattern  is  seen  in 
              Granulomatous  prostatitis 
             Prostatitis  with  crush  artifacts. 
 
           In  general,  recognition  of  this  differential  diagnosis  coupled  with  
careful  routine  microscopy  will  lead  to  correct  diagnosis.  In  some  instances,  
however  ancillary  immunohistochemical  studies  aimed  at  identifying  prostatic  
basal  cells  (34βE12,  CK  5/6 , p63),  prostatic  secretory  cells  (PSA,  PAP,  CD  57)  
neuroendocrine  cells  (chromogranin,  synaptophysin)  and  inflammatory  cells  
(LCA,  CD  68)  may  be  required  to  resolve  a  diagnostic  dilemma. 
                   The  new  marker  methyl  acyl  -  COA  racemase  (P50  4s)  appears  to  
be  of  valve  in  supporting  a  diagnosis  of  adenocarcinoma,  especially  when  
one  is  dealing  with  small  foci. 
               It  is  important  to  always  be  aware  of  the  potential  of  false  -  
positive  cancer  diagnosis,  when  looking  at  prostatic  biopsies  and  to  utilize  
appropriate  consultation  and  ancillary  studies  to  arrive  at  a  confident  and  
correct  diagnosis.
(44) 
 
 
 
 
 
 
 
OBSERVATIONS  AND  RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        CHART 1 : INCIDENCE OF PROSTATIC LESIONS COMPARED TO ALL CASES 
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                           OBSERVATION  AND  RESULTS 
 
 
The  present  study  deals  with the evaluation of    various   histopathological   
lesions  in  Prostatic  specimens  and  the  role  of   basal  cell  markers   in  
differentiating  carcinoma  and  benign  lesions. 
TABLE  1: 
              INCIDENCE  OF  PROSTATIC  LESIONS  COMPARED  TO  ALL  CASES 
PERIOD TOTAL NO OF 
SPECIMENS 
NO OF PROSTATIC 
SPECIMENS 
PERCENTAGE 
Jan2010- Dec2010 4556        36 0.34% 
Jan2011-Dec2011 4840       73 0.69% 
Jan2012-Mar2012 1137       41 0.39% 
Total 10,533       150 1.42% 
 
         A total  of  10533  surgical  specimens  received  in  the  department  of  
pathology,  Thanjavur  Medical  College,  Thanjavur  during  the  study  period,  of  
which  prostatic  specimens  constituted  150  cases  (1.42%)  cases. (chart 1)      
CHART 2 : FREQUENCY OF BENIGN, MALIGNANT LESIONS COMPARED TO 
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TABLE 2: 
                   FREQUENCY  OF  BENIGN  AND  MALIGNANT  LESIONS   
 
GROSS BENIGN LESIONS MALIGNANT TOTAL 
TURP 121 9 130 
TRUCUT 9 11 20 
TOTAL 130  (86.67%) 20  (13.33%) 150  (100%) 
 
PROSTATIC LESIONS: 
              Out of 150 prostatic specimen  received,  130  were  benign  lesions  and  
prostatic  malignancy  was  diagnosed  in  20  cases.  Incidence  of  benign  lesions  
was  86.67%    and  malignant  lesions    was  13.33%  in  this  study. (chart 2) 
Nature of prostatic specimen: 
              Among the benign lesions, 121 cases  were  reported  in  TURP specimen 
and   9  cases  in  Trucut biopsy.    Malignant  lesions   were  diagnosed in  9  TURP  
samples  and    11  in  Trucut  biopsy samples. 
 
 
 
 
CHART 3 : INCIDENCE OF PROSTATIC CARCINOMA  
 
 
 
 
 
 
 
TABLE 3: 
                                      INCIDENCE  OF  PROSTATIC  CARCINOMA 
Period Total no: 
specimens 
Total 
neoplasm 
Total 
malignancy 
Prostatic 
malignancy 
Percentage 
Jan2010-
Dec2010 
4556 1520 900 2 0.22% 
Jan2011-
Dec2011 
4840 1380 887 9 1.02% 
Jan2012-
mar2012 
1654 403 232 9 1.02% 
Total 11050 3303 2019 20 2.26% 
 
             Out  of  11050  total  specimens, received  during  study period, total  
malignancies  were  2019  and  out  of  these,  prostatic  malignancy  constituted  
2.26%. (chart 3) 
 
 
 
 
 
 
                              
                            CHART 4: AGE INCIDENCE OF VARIOUS PROSTATIC LESIONS 
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TABLE 4: 
                    AGE  INCIDENCE  OF VARIOUS PROSTATIC LESIONS 
S.No Age  (Years) Benign  lesions Malignant Total 
1 40  -  49 3  (2.3%)  (0%) 3  (2%) 
2 50   - 59 32  (24.62%) 5  (25%) 37  (24.67%) 
3 60  -  69 62  (47.69%) 9  (45%) 7  (47.33%) 
4 70  -  79 25  (19.24%) 3  (15%) 28  (18.67%) 
5 >80 8  (6.5%) 3  (15%) 11  (7.33%) 
 TOTAL 130  (100%) 20  (100%) 150  (100%) 
           
              Among  130  benign  lesions,  majority  of  the  benign  cases  belonged  to  
the  age  group  of  60 - 69  years.  Youngest  case  was  42  years  and  oldest  was  
83  years. (chart 4) 
               Among  20  malignant  lesions,  majority  of  the  cases  were  seen  in  age  
group  of   60-69 years.  Youngest  person  was  55 years  and  the  oldest  person  
was  81  years   old  in  this  category. 
 
 
 
 
 
TABLE 5: 
         MICROSCOPIC FINDINGS IN BENIGN LESIONS: 
Sl.No. Findings No.of  cases 
1 Adeno fibromyomatous  hyperplasia 90 
2 Basal  cell  hyperplasia  
1.complete 
2.incomplete 
 
2 
6 
3 Squamous  metaplasia 2 
4 Abscess 3 
5 Chronic  prostatitis 8 
6 Atrophy 7 
 
Microscopic  features  in  Benign  lesions: 
                In  the  present  study  90  prostatic  specimens(fig1A&1B)  were  
showing  nodular hyperplasia.  The  lesions  were  composed  of  varying  
proportion  of  epithelium  and  stroma.  Corpora  amylacea  was  seen  in  
majority  of cases.  8  cases(fig2)  were  showing  chronic  inflammatory  cell   
 
 
 
 
                                      CHART 5: MICROSCOPIC FINDINGS IN BENIGN LESIONS 
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infiltrate  composed  of  admixture  of  lymphocytes  and  plasma  cells.  3  case  
showed  aggregate  of  neutrophils  in  and  around  the  acini  in  the  form  of  
abscess. 
                8  cases  were  showing  nodular  hyperplasia  associated  with  basal  cell 
hyperplasia characterised  by  basal  cell  proliferation.(fig4A&4B)  Out  of  these  2  
showed  complete,  6  showed  incomplete  BCH.  2  cases  of  nodular hyperplasia  
were  showing  squamous  metaplasia.(fig3) 7  cases  of  nodular hyperplasia  with  
atrophy  was  also found.(fig5) (chart 5) 
 
 
 
 
 
 
 
 
 
 
 
 
CHART 6: PROSTATIC INTRAEPITHELIAL NEOPLASIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 6: 
     PROSTATIC  INTRAEPITHELIAL  NEOPLASIA  : 
SL.  NO. PIN  LESIONS NO.  OF  CASES 
1 LGPIN  WITH  NODULAR 
HYPERPLASIA 
3   (2.31%) 
2 HGPIN  WITH  NODULAR 
HYPERPLASIA 
9  (6.92%) 
3 LGPINWITHCARCINOMA NIL 
4 HGPINWITHCARCINOMA 3  (15%) 
 
 
 
              All  the  sections  of  Nodular  hyperplasia  and  Prostatic  adenocarcinoma  
were  carefully  examined  for  the  evidence  of  PIN  and  graded  when  present.  
                Low  grade  PIN  was  noted  in  3  cases(fig7A)   and  high  grade  PIN  in  
9  cases(fig7B) out of 130 cases of nodular hyperplasia & 3 cases of high grade pin 
out of 20 cases of adenocarcinoma.(figures8-13) (chart 6)  
 
 
 
 
 
TABLE 7: 
        GLEASON’S GRADING SYSTEM FOR CARCINOMA : 
S.  NO. PATH  NO. HPE  DIAGNOSIS GLEASON’S  
GRADE 
GLEASON’S  
SCORE 
1 500/10 Adenocarcinoma 4+3 7 
2 318/10 Adenocarcinoma 4+3 7 
3 1185/11 Adenocarcinoma 3+2 5 
4 2346/11 Adenocarcinoma 3+3 6 
5 2676/11 Adenocarcinoma 4+2 6 
6 3036/11 Adenocarcinoma 3+3 6 
7 3615/11 Adenocarcinoma 3+4 7 
8 3953/11 Adenocarcinoma 3+2 5 
9 4083/11 Adenocarcinoma 4+3 7 
10 4448/11 Adenocarcinoma 2+2 4 
11 812/12 Adenocarcinoma 4+4 8 
12 5/12 Adenocarcinoma 4+3 7 
13 7/12 Adenocarcinoma 3+3 6 
14 115/12 Adenocarcinoma 4+2 6 
 
 
15 181/12 Adenocarcinoma 3+3 6 
16 523/12 Adenocarcinoma 3+4 7 
17 1874/12 Adenocarcinoma 3+3 6 
18 527/12 Adenocarcinoma 3+4 7 
19 1874/12 Adenocarcinoma 4+4 8 
20 55/12 Adenocarcinoma 3+4 7 
 
Gleason’s  score: 
                All  of  these  20  malignant  cases  were  graded  using  Gleason’s  scoring  
system.  Primary  grade  is  assigned  to  dominant  pattern  and  secondary  grade  
to  subdominant  pattern.  The  two  numeric  grades  are  added  to  obtain  the  
combined  Gleason’s  score.  In  tumors  with  one  pattern,  the  number  is  
doubled. 
 
 
 
 
 
 
 
 
CHART 7: INCIDENCE OF CARCINOMA WITH REFERENCE TO GLEASON’S SCORE 
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TABLE 8 : 
INCIDENCE OF CARCINOMA WITH REFERENCE TO GLEASON’S SCORE 
Gleason’s  score No.  of  cases % 
4 1 5 
5 2 10 
6 5 25 
7 10 50 
8 2 10 
Total 20 100% 
 
 
Gleason score  of   2-4    was  seen  in  1 case(5 %).  Gleason  score  of   5-7    
was  seen  in  17  cases(85%).  Gleason  score  of 8-10 (10%) was  seen  in  2 cases . 
(chart 7) 
 
 
 
 
 
 
 
                                      CHART 8: FINAL HISTOPATHOLOGICAL DIAGNOSIS 
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TABLE 9: 
                              Final  Histopathological  Diagnosis 
SL.NO. DIAGNOSIS NO.  OF  CASES % 
1 Nodular hyperplasia 
With  prostatitis 
90 
8 
60 
5.33 
2 Basal  cell  hyperplasia 8 5.33 
3 With  abscess 3 2 
4 Squamous  metaplasia 2 1.33 
5 Atrophy 7 4.68 
6 PIN 
LGPIN 
HGPIN 
 
3 
9 
 
2 
6 
7 Adenocarcinoma 20 13.33 
                    
(chart 8) 
 
 
 
 
 
IMMUNOHISTOCHEMISTRY 
                  A  total  of  12  cases  were  selected,  comprising  4 cases  of benign  
prostatic  hyperplasia,4 cases  of  PIN , 4cases  of  prostatic  carcinoma  to  study  
the  immunohistochemical  reaction  of  prostatic  basal  cells  towards HMWCK  
and P63. 
 
EVALUATION  OF  IHC 
                In  majority  of  benign  prostatic  glands,  both  antibodies,  
demonstrated,  intense  positivity  for  basal  cell  -  specific  immune  staining  
with  HMWCK  (localized  to  the  cytoplasm)  and  p63  (localized  to  the  
nucleus).   
     For  both  stains  positive  staining  was  taken  as  an  evidence  of  
benignity  whereas  negative  staining  was  taken  as  evidence  of  malignancy.  
Basal  cell  staining  was  considered  positive  only  if  > 10 %  of  the  glands  were  
stained  and  negative  if  only  ≤  10  %  of  the  gland  were  stained. 
 
 
 
 
 
 
TABLE 10: 
THE RESULT  OF  FOLLOWING  CASES  AFTER  BEING  TREATED WITH  
HMWCK  AND  p63  IMMUNOSTANING 
SL.NO. PATH NO. HPE HMWCK(+VE/-VE) p63  (+VE/-VE) 
1 3902/10 BPH (Basal cellhyperplasia) Positive Positive 
2 889/11 BPH (Cystic atrophy) Positive Positive 
3 530/12 BPH (Crush artifact) Negative Positive 
4 2413/12 BPH Negative Positive 
5 4104/12 HGPIN Positive Positive 
6 3954/11 HGPIN Positive Positive 
7 3209A/11 HGPIN Negative Negative 
8 3385/11 HGPIN Positive Positive 
9 3615/11 Prostatic  adenocarcinoma Negative Negative 
10 704/12 Prostatic adenocarcinoma Negative Negative 
11 812/12 Prostatic adenocarcinoma Negative Negative 
12 1185/11 Prostatic adenocarcinoma Negative Negative 
 
 
 
 
 
 
  
CHART 9: RESULTS OF HMW-CK STAINING IN BENIGN, PREMALIGNANT AND MALIGNANT PROSTATIC 
LESIONS 
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TABLE 11: 
RESULTS OF HMW-CK STAINING IN BENIGN, PRE MALIGNANT AND MALIGNANT 
PROSTATIC GLANDS 
RESULTS OF HMWCK STAINING BENIGN PREMALIGNANT MALIGNANT TOTAL 
POSITIVE 2 3 0 5 
NEGATIVE 2 1 4 7 
TOTAL 4 4 4 12 
 
 
Sensitivity of HMW-CK       =  62.5%             Statistical inference 
Specificity of HMWCK         =  100%              X2=4.800,  d.f. =  2 & p=.091           
Positive predictive value    =  100%              p=.091<.05 
(chart 9) 
 
 
 
 
 
 
 
 
 
 
CHART 10: RESULTS OF p63 STAINING IN BENIGN, PREMALIGNANT   AND MALIGNANT PROSTATIC 
LESIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
Begnign Premalignant Malignant
P63 STAINING 
Negative
Positive
 
 
TABLE 12 : 
RESULT  OF  p63  STAINING  IN  BENIGN, PREMALIGNANT  AND  MALIGNANT  
PROSTATIC  GLANDS 
RESULTS  OF  p63 STAINING BENIGN PREMALIGNANT MALIGNANT TOTAL 
POSITIVE 4 3 0 7 
NEGATIVE 0 1 4 5 
TOTAL 4 4 4 12 
       (chart 10) 
Sensitivity  of  p63                                            =  87.5%       Statistical  inference           
Specificity  of  p63                                              =  100%        X
2=8.914,d.f.=2&p=.012 
Positive  predictive  value  of  p63   =  100%        p=.012<.05 
 
From  table  11  and  12,  it  is  apparent  that  all  of  the  malignant  glands  
showed  total  absence  of  HMW-CK  and  p63  staining  leading  to  a  specificity  
of  100%  for  both  HMW-CK  and  p63 (fig25A&B) 
Out  of  4  benign  glands,  only  2  showed  positivity  for  HMWCK  and  all  
the  4  showed  positivity  for  p63  staining. (figures 14—21) 
 
 
Out  of  4  premalignant  lesions  studied  with  HMWCK  and  p63,  3  
showed  positivity  for  both  HMWCK  &  p63  and  1  showed  negativity  for  the  
both.( figures 22 A&B, 23A&B)  
The  sensitivity  in  identifying  basal  cells  in  benign  glands  was 62.5%     
and  87.5%     for  HMW-CK  and  p63  respectively.  The  positive  predictive  value  
was  100%  for  both  HMW-CK  and  p63. 
The  results  of  our  study  demonstrates  that  p63 ,  like  HMW-CK,  is  
specific  for  basal  cells  in  the  prostate  gland  and  therefore  are  negative  in  
areas  of   prostatic carcinoma.   After  statistical  analysis,   p63   is  found  to  be  
more  sensitive  than  HMWCK  in  staining  benign  basal  cells  in  TURP  
specimens. 
 
 
 
 
 
 
 
 
 
Figure 2 - Chronic prostatitis –showing glands with the admixture of chronic 
inflammatory cells(H&E) 10X 
 
 
Figure 3 - Inflammation with squamous metaplasia of glandular epithelium – 
showing cells with abundant eosinophilic cytoplasm& distinct cell 
borders(H&E)40X 
 
 
 
Figure 1A - Benign prostatic hyperplasia – Showing hyperplasia of both 
glandular and stromal components(H&E)10XFigure 1B - BPH – stromal 
hyperplasia – showing predominantly stromal component composed mainly of 
fibrous tissue (H&E)10X 
 
 
 
 
 
 
 
 
 
Figure 4A – Basal cell hyperplasia- complete form showing solid nests of cells 
without luminal differentiation(H&E)40X 
 
Figure 4B - Basal cell hyperplasia –Incomplete form showing solid nests of basal 
cells with luminal differentiation(H&E)40X 
 
 
 
 
 
Figure 5 – Cystic atrophy –showing dilated acini, lined by low cuboidal to 
flattened atrophic cells.(H&E)10X 
 
Figure6-  Benign prostatic tissue with crush artifact(H&E)10X 
 
 
 
 
 
 
 
 
 
 
 
Figure 7A – Low grade prostatic intraepithelial neoplasia –Showing slight 
enlargement of nuclei (H&E) 40X 
 
 
 
 
 
 
 
 
 
Figure 7B – High grade prostatic intraepithelial neoplasia –showing prostatic 
gland with stratified lining cells exhibiting cytological atypia(H&E) 40X 
 
 
 
Figure 8– Prostatic adenocarcinoma – needle biopsy –(H&E) 4X 
 
Figure 9– Prostatic adenocarcinoma –Showing characteristic circumferential 
perineural invasion  of tumor cells(H&E) 40X 
 
 
Figure 10- Prostatic adenocarcinoma – Gleason’s pattern 2 –composed of less 
uniform, single, separate, loosely arranged glands(H&E) 10X 
 
igure 11 - Prostatic adenocarcinoma – Gleason’s pattern 3 –composed of small 
to medium sized glands showing angulations with focal cribriform pattern(H&E) 
10X 
 
 
 
Figure 12A - Prostatic adenocarcinoma – Gleason’s pattern 4A – showing fused 
glands with raggedly infiltrating edges.(H&E)10X 
Figure 12B - Prostatic adenocarcinoma – hypernephroid pattern  Gleason’s 
grade 4B – showing features same as 4A with large pale cells (H&E)40X 
 
 
 
Figure 13 - Prostatic adenocarcinoma – Gleason’s pattern 5 –showing solid 
sheets of cells without glandular differentiation.(H&E) 40X 
  
Figure 14 – BPH - Diffuse cytoplasmic positivity for HMWCK –10X 
 
 
 
Figure 15 - BPH- Diffuse nuclear positivity for p63 - 10X 
 
Figure 16 - BCH- Diffuse cytoplasmic positivity for HMWCK-40X 
 
 
 
Figure 17 - BCH- Diffuse nuclear positivity for p63 - 10X 
Figure 18 - Cystic atrophy-diffuse cytoplasmic positivity for HMWCK– 
40X 
 
 
Figure 19 - Cystic atrophy-diffuse nuclear positivity for p63 – 10X 
Figure 20 – Crush artifact – Negative for HMWCK– 40X 
 
 
 
Figure 21 – Crush artifact – Diffuse nuclear positivity for p63 – 40X 
Figure 22A – Low  grade prostatic intraepithelial neoplasia – Diffuse 
cytoplasmic positivity for HMWCK – 40X 
 
 
 
Figure 22B - Low grade prostatic intraepithelial neoplasia – Diffuse 
nuclear positivity for p63 – 40X 
Figure 23A - High grade prostatic intraepithelial neoplasia – Patchy 
cytoplasmic positivity for HMWCK – 10X 
 
 
 
Figure 23B - High grade prostatic intraepithelial neoplasia – Patchy 
nuclear positivity for p63 – 40X                                                             
Figure 24 - Adenocarcinoma with normal adjacent glands  showing 
nuclear positivity for p63 ,acting as a good positive internal control – 
10X 
 
 
 
Figure 25A - Adenocarcinoma – Negative for HMWCK – 40X 
 
Figure 25B - Adenocarcinoma – Negative for p63 – 40X 
 
 
 
 
 
 
 
 
 
 
                               DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
                                              DISCUSSION 
                
Prostatism  is  a  common  malady  in  the  geriatric  age  group. 
  BPH  and  carcinoma  of  the  prostate  are  increasingly  frequent  with  
advancing    age.        The  various  histological  appearances  of  BPH  and prostatic  
adenocarcinoma  are  well  known  and  have  been  described  and  illustrated  
extensively  in  the  literature. 
            These  two  common  urologic  conditions  among  elderly   men,  share  not  
only  a  similar  hormonal  milieu  within  the  prostate,  but  also  several  
epidemiologic  and  clinical  factors.  Both  conditions  increase  with  advancing  
age,  both  require  androgens  for  growth  and  development  and  both  respond  
to  antiandrogenic  therapy. Both  share  similar risk  factors  such  as  insulin  like  
growth  factors,  insulin  and  obesity. 
              This  study  was  undertaken  to  evaluate  the  various  histological  
lesions  in  the  prostatic  specimens  and  to  evaluate  the  role  of   IHC  in  
diagnostically  challenging  cases.  In  this  study,  150  prostatic  lesions  were    
analysed.  These  formed  1.42%   of  the  total  surgical  specimens  received  
during  the  study  period. 
 
 
 
 
HISTOPATHOLOGICAL  DIAGNOSIS: 
 
             The  present  study  showed  that  majority,   86.67%    of    cases  were  
benign  lesions  of  which  nodular  hyperplasia  alone   constituted   60%        
cases,  followed  by  13.33%  of  adenocarcinoma.              
              According  to  study  by  Bostwick  et al  nodular hyperplasia  is  composed  
of  varying  proportion  of  epithelium  and  stroma.  The  most  common  nodules  
reported  in  their  study  was  adenofibromyomatous  nodules  which  contained  
all   elements.
(10 
In  a  study,  Mittal  et al 
(14)
 showed  92.98%  of  cases  of  benign  lesions  
followed  by  7.02%  of  malignant  cases. 
 
 
 
 
 
 
 
 
TABLE 13: 
HISTOPATHOLOGICAL DIAGNOSIS IN DIFFERENT STUDIES  
Sl.No. HP  diagnosis Mittal  BV  et al  
(14) 
Elizabeth  et  al 
(2005)  (30) 
Present  study 
1 Nodular   hyperplasia 103 (55.67%) 1029 (88.5%) 90 (60%) 
2 Basal  cell hyperplasia 10(5.4%) Nil 8 (5.33%) 
3 Squamous  metaplasia 19 (10.27%) Nil 2 (1.33%) 
4 Prostatitis 30 (16.24%) Nil 8 (5.33%) 
5 Atrophy 3 (1.62%) Nil 7  (4.67%) 
6 PIN Nil 7 (0.6) 15  (10%) 
7 Carcinoma 13  
(7.02%) 
127 (0.9%) 20  (13.34%) 
8 Total no. of Prostatic 
specimens 
185 1163 150 (100%) 
 
 
 
 
 
HYPERPLASIAS: 
                   In  the  present  study,  the  incidence  of  benign  lesions  was 86.67 %.     
nodularhyperplasia  alone  was  noted  in    60  %,     out  of  which majority  of  
cases  were  encountered  in  the  6th      and    7th      decade. Other  cases  includes  
those in  which  nodularhyperplasia  occurred  together  with  other  lesions  like  
PIN,  basal  cell  hyperplasia,  metaplasia,  prostatitis  and  atrophy.    
 
TABLE 14: 
AGE  SPECIFIC  INCIDENCE  OF  NODULAR  HYPERPLASIA –  
A COMPARATIVE  ANALYSIS: 
S.No. Study 40 -49 
years 
50 – 59 
years 
60 – 69 
years 
70 – 79 
years, >80 
1 Anjorin et al
(5) 2.3% 13.6% 40.4% 23.4% 
2 Elizabethgeorge 
and sosama
(30) 
7.82% 25.97% 32.67% 16.94% 
3 Present  study 2.3% 24.62% 47.69% 19.24% 
 
 
 
 
BASAL CELL HYPERPLASIA(46) : 
                      
       Basal cell hyperplasia  is  usually  seen  in  cases  of  nodular  
hyperplasia.Basal cell  hyperplasia  is  typically  found  in  the  transition  zone  and  
is  therefore  usually  identified  in  the  transurethral  resection. 
                 In  a  present  study  8  cases  showed  Nodular  hyperplasia  along with  
basal  cell  hyperplasia  in  the  age  group  of  55  -  75  years.  It  is  characterized  
by  small  uniform  darkly  staining  basal  cells  forming  solid  nests,  tubules  and  
cords  with   peripheral  palisading  appearance.   
                 There  are  2  types  in  basal  cell  hyperplasia.  In   complete  form,  solid  
nests  of  dark  blue  cells  are  seen  with  no  secretory  cell  differentiation,  
whereas  in  the  incomplete  form,  secretory  cells  with  clear  cytoplasm  line  
the  small  residual  lumina  with  multiple  layers  of  basal  cells  surrounding  
them. 
In  both  the  types  basal  cells  show  scant  cytoplasm  with  round,  oval  
or  spindled  hyperchromatic  nuclei  indistinct  nucleoli  which  may  be  
prominent  in  some  cases. In  this  study, 2 cases  showed complete  hyperplasia.  
6 Cases  showed  incomplete  hyperplasia. 
 
 
             In  a  study  by  clearly  et al,
(18)
  all the  patients  were  above  the  age  of  
60  years  and  all  had  nodular hyperplasia, in  addition  to  basal  cell  
hyperplasia. 
           The  present study  showed  2  cases  of  squamous  metaplasia,  in  addition  
to  nodular  hyperplasia,  thus  accounting  for   1.33%  of  total  cases  studied.  
However  study  by  Mittal  et al 
(14)
 showed  Metaplastic  epithelium  in  10.27%            
of  cases. 
PROSTATITIS: 
TABLE 15:  
 INCIDENCE  OF  PROSTATITIS: 
Chronic  Prostatitis 8  (72.72%) 
Abscess 3  (27.28%) 
Total 11  (100%) 
 
In  the  present  study,  out  of  150  cases   11  cases  had  Prostatitis. 
In  a  study  by  Stillwell  et al,  25  cases  of   prostatic  abscess  showed  sheets  of  
neutrophils  in  and  around  the  acini. 
 
 
In  cases  of  chronic nonspecific  prostatitis,  lymphocytes,  plasma  cells  
and  macrophages  were  seen.  Bostwick  in  his  study  has  reported  more  cases  
of  chronic  abacterial  as  compared  to  bacterial  prostatitis. 
ATROPHY(46) : 
              Glandular  atrophy  of  prostate  is  commonly  seen  in  areas  of  nodular  
hyperplasia.Atrophy  is  more  common  in  peripheral  zone  but  it  can  be  seen  
the  central  and  transitional  zone  also. 
  According  to  the  pattern,the  atrophy  can  be  classified  as  lobular,  
sclerotic,  cystic,  linear  or  streaming . But  in  all  the  types  cytological  features  
are  similar  in  the  form  of  shrunken  dark  cells  with  high  N/C  ratio,  uniform  
nuclei  with  no  nuclear  membrane  or  chromatin  abnormality.  In   areas  the  
cytological  features  are  difficult  to  appreciate  because  of  marked  secretory  
cell  atrophy. 
              In  the  present  study,  7  cases  had  atrophy  along with  Nodular  
hyperplasia  out  of  150  cases. Mittal BV  et  al
(14)
  showed  1.32%  cases  of  
atrophy,  present  along  with  Nodular  hyperplasia  in  their  study.  Wenle 
WangMD  et  al 
(98)
 showed  4.35%  of  cases  with  partial  atrophy. 
 
 
 
PROSTATIC INTRAEPITHELIAL NEOPLASIA 
                                                      
                In  a  present  study,  15 cases  showed  PIN . 3  cases  of  LGPIN  was  
associated  with  nodular  hyperplasia  and  3  cases  showed HGPIN  associated  
with  Prostatic  carcinoma.  9  cases  showed  HGPIN with  Nodular  hyperplasia.  
                LGPIN  was  characterized  by  epithelial  crowding,  stratification  and  
anisonucleosis.HGPIN  was  characterized  by  pronounced  epithelial  crowding,  
nuclear enlargement,  hyperchromasia  and  luminal  bridging  giving  a  cribriform   
appearance.  Prominent  nucleoli  was  also  seen.  Adjacent  area  showed  small  
glands  infiltrating  the  stroma. 
              The  prevalence  and  extend  of PIN  increases  with  patient  age.  Most  
foci  of  PIN  in  young  men  were  low  grade  with  increasing  frequency  and  
volume  of  high  grade  PIN  with  advancing  age. 
Race  and  geographic  location  also  appear  to  influence  the  incidence  of  PIN.  
African  -  American  men  had  a  greater  prevalence  of  PIN  than  Causatians  in  
the  50  -  60  years  of  age  group.  African  -  American  also  had  a  highest  
incidence  of  cancer. 
 
 
 
 
TABLE 16: 
INCIDENCE  OF  PIN    WITH  AND  WITHOUT  PROSTATIC  CARCINOMA. 
Authors PIN  without  carcinoma % PIN with  carcinoma  % 
McNeal  f Bostwick  et al
(13) 43% 82% 
Troncosa et al
(13) 17.9% 72.1% 
Kovi et al
(56) 46% 59.3% 
Rekhi B et al
(81) 11.2% 86.9% 
Present  study 9.23% 15% 
 
According  to  this  study,  PIN  was  found  in 15% of  Prostate  with  carcinoma  
and 9.23%  Prostate  without  carcinoma. 
TABLE 17: 
INCIDENCE  OF  HGPIN  IN  PROSTATES  WITH  CARCINOMA. 
Authors Incidence  of  HGPIN  in  Prostatic  adenoca  % 
McNeal  Bostwick  et  al  (1986)
(13) 33% 
Kovi  et  al
(56) 33% 
Present  study 15% 
 
 
  
                  The  prevalence  of  high  grade  PIN   in  TURP  for  carcinoma  is  
remarkably  high  reflecting  the  strong  association  with  malignancy. 
There  are  many  evidences  to  suggest  the  relationship  of  HGPIN  and  
Prostatic  adenocarcinoma. 
 
         1.   The  incidence  and  extent  of  both  lesions  increases  with  patient  age. 
         2.  There  is  an  increased  frequency,  severity  and  extent  of  HGPIN  in  
prostatic  carcinoma. 
         3. Both  HGPIN  and  carcinoma  are  multifocal  with  a  predominant  
peripheral  zone  distribution .   
Histological  atypia  observed  in  HGPIN  is  virtually  indistinguishable  from  
that  of  Prostate  cancer  except  that  in  HGPIN  the  basal  membrane  is  still  
intact.  As  HGPIN  progresses,  the  likelihood  of  basal  cell layer  disruption  
increases.
(49)
 
 
 
            
 
 
                           PROSTATIC  CARCINOMA 
 
Prostatic  cancer  contributes  to  the  overall  cancer  burden,  being  the  
most  frequent  malignancy  in  men  world  wide. The  number  of  cases  had  
continuously  increased  over  the  past  decades,  due  to  higher  life  expectancy,  
western  life  style  characterized  by  a  high  calorie  diet  and  lack  of  physical  
exercise.                           
            It  is  the  second  most  frequently  diagnosed  cancer  of  men  and  fifth  
most  common  cancer  overall.  Incidence  rates  of  prostate  cancer  vary  by  
more  than   25  fold   worldwide,  highest  rates  are  in Australia/Newzealand,  
Western  and  Northern  Europe,  North  America,  largely  because  the  practice  
of  PSA  testing  and  subsequent  biopsy  has  become  widespread  in  those  
regions.
( 43) 
              Epidemiological  data  suggest  the  black  people  are  more  susceptible  
followed  by  white  people,   while  the  Asians  have  the  lowest  risk.
(28,53) 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 18 : 
 COMPARISION  OF  INCIDENCE  OF  PROSTATIC  CARCINOMA(73) 
  
S.no Name  and year of study Prevalence 
1 Population based cancer registry  Delhi 2001-2003 2.7% 
2 Population  based  cancer  registry  Mumbai  2001 – 2003 2.8% 
3 Population  based  cancer registry Bangalore  2001  -  
2003 
2.5% 
4 Population  based  cancer  registry  Sikkim  2003 - 2004 0.5% 
5 Population  based  cancer  registry  Bhopal  2001 – 2003 2.3% 
6 Population  based  cancer  registry  Assam  2007 – 2008 0.7% 
7 Population  based  cancer  registry  Chennai  2001 – 2003 1.6% 
8 Present  study  2010 - 2012 2.26% 
     
The  prevalence  of  prostate  cancer  as  indicated  by  various  studies  in  
the  journals  and  the  literature  is  given  in  the  above  table.  In  our  study,  the  
prevalence  was  2.26%  , which  is  in  close  correlation  with  other  studies. 
 
 
 
TABLE 19: 
AGE  INCIDENCE  OF  PROSTATIC  CARCINOMA  IN  DIFFERENT  STUDIES 
AUTHORS 40  -49 50  -59 60  -69 70  -79 >80 
Lee and Shanmugaratnam  et  al 
(99)
  4.3% 8.3% 10.6% 13.6% 20% 
L Stanford  et  al
(44) 0.6% 6% 20% 18.3% Nil 
Hamwakyoma  et  al
(29) 0.8% 16.7% 39.5% 31.6% Nil 
Roberto  Deangless  et  al(83) 2% 2.3% 33% 64% Nil 
F Aragona  et  al
(33) 1.5% 4.5% 7.1% 11% Nil 
Anjorini  et  al
(5) 2.3% 13.6% 40.4% 23.4% Nil 
Present  study 0% 25% 45% 15% 15% 
 
         In  the  present  study,  peak  incidence  of  prostatic  carcinoma  was  seen  
in  age  group  of  60  -  69  a  decade  earlier  than  PIN. 
           Many  recent  studies  show  a  higher  incidence  of  prostatic  carcinoma  in  
the  age  group  of  60  -  80. 
          
 
 
 
TABLE 20: 
FREQUENCY  DISTRIBUTION  OF  GLEASON’S  SCORE  AT 
PRESENTATION. 
Author Gleason’s  score No.of  pts. % age 
Dr.Hamwakyoma  
and   
Dr. JLMagandi
(29) 
2  -4 6 5.3% 
5  -7 69 61.1% 
8  -10 38 33.6% 
Total 113 100% 
 
 
 
 
PRESENT STUDY 
2  -4 1 5% 
5  -7 17 85% 
8  -10 2 10% 
Total 20 100% 
 
          In  the  present  study,  20  cases  of  adenocarcinoma  prostate  were  seen   
accounting  for  13.33%  of  the  cases. 
          All  these  20  malignant  cases  were  graded  using  Gleason’s  scoring   
system.  Majority  of  our  cases  showed  moderate  to  poor  differentiation. 
 
 
IMMUNO HISTOCHEMISTRY 
  Immunohistochemical  detection  of  basal  cells  is  widely  used  to  help  in  
the  diagnosis  or  exclusion  of  prostatic  carcinoma  in  a  diagnostically  
challenging  cases.    HMW-CK  has  thus  far  been  the  most  commonly  used  
IHC  stain  in  the  diagnosis  of  prostatic  carcinoma. 
             When  dealing  with  small  foci  of  atypical  glands  with  some  suspicious  
(but  not  diagnostic)  architectural  or  cytologic  features  of  prostatic carcinoma,  
negative  HMW-CK  staining  in  the  atypical  glands  would  favour  a  diagnosis  
of  adenocarcinoma.             
              p63  has  recently  generated  much  interest  due  to  its  expression  in  
the  basal  cells  of  the  prostate,  and  it  is  essential  for  prostate  development. 
Signorett  et  al 
(88)
 also  highlighted  the  role  of  p63  in  the  development  of  
prostate  gland  and  showed  that  p63  is  expressed  in  virtually  all  the  basal  
cells  of  prostatic  glands,  including  a  subset  negative  for  HMW-CK. 
The  resuls of  our  study  demonstrates  that  p63,  like  HMWCK  is  specific  
for  basal  cells  in  the  Prostate  gland. 
            None  of  the  4  case  with  histologically  unequivocal  prostatic carcinoma  
demonstrated  immunoreactivity  for  either  HMWCK  or  p63  (100%  specificity).   
 
 
          Among  the  8  cases  which  included  both  benign  and  premalignant  
lesions, with  regard  to  HMWCK  staining  in our study  in  5  cases  [2  Benign  
and  3  Premalignant  (PIN)]  showed  positivity,  3  cases  (2Benign  and  1  
premalignant)  showed  negativity.  Absence  of  basal  cell  staining  in  these  
cases  was  due  to  the  effects  of  prolonged  formalin  fixation,  as  extended  
formalin  fixation  decreases  the  HMWCK  antigeniciy.
(50)
   
             With  regard  to  p63  staining  in  our  study  out of  8  cases,  7  cases  [4  
benign  and  3  premalignant  (PIN) ] showed  positivity  and  1 case 
[1premalignant]  showed  negativity.  This  correlated  with  the  study  of  shah  et  
al 
(89)
 who  reported  the  absence  of  basal  cel  staining  both  with  HMWCK  and  
p63. 
              This  absence  of  basal  cell  staining  may  be  attributed  to  the  
diminished  or  absence  gene  expresson  of  basal  cell  markers,  technical 
variables,  including  those  resulting  from surgical  procedures  and  antigen  
retrieval  methods  could  be  another  important  source  of  negative  basal  cell  
 IHC  reactions.
(69,50)
                      
 
 
             Multhaupt  et  al,
(68)
  also  found  that  88%  benign  gland  in  the  
transition  zone  obtained  by  trans  urethral  resections  of  the  prostate  lost  
their  HMWCK  antigenicity  if antigen  retrival  was  not  used. 
              In  our  study,  one  case  of  benign  prostatic  hyperplasia  with  crush  
artifact,  showed,  lack  of  staining  of  basal  cells  with HMWCK  but  showed  
positivity  with  nuclear  p63  staining.  This  correlated  with  the  study  of  
Michael  et (64)  who  showed  same  effect as  above. 
              In  one  case  of  prostatic  adenocarcinoma(fig24)  good  positive  internal  
control  staining  was  seen  with  p63.  That  means,  no staining  was  seen in  
malignant  glands  but  the  basal  cells  in  benign  glands  that  was  present  
adjacent  to  the  malignant  gland  were  stained  with  p63. 
Our  study  showed  that  the  sensitivity  in  identifying  basal  cells  in  
benign  glands  is  62.5%   and 87.5%  for   HMWCK  and  p63,   respectively.  
           Hence,  p63  is  slightly  more  sensitive  in  identifying  basal  cells  than  
HMWCK   according  to  our  study. 
           Shah  et  al 
(89)
 similarly  found  that  p63  is  more  sensitive  than  HMWCK  
in  identifying  the  basal  cells,  particularly  in  TURP  specimens,  offering  slight  
advantage  over  HMWCK  in  diagnostically  challenging  cases.  p63  may  be  
used  as  an  alternative  to  HMWCK  stain  for  difficult  prostatic  lesion. 
 
 
       
 
 
 
 
 
 
                           CONCLUSION                               
 
 
 
 
 
 
 
 
                                         CONCLUSION 
 
In  the  present  retrospective  study,  comprising  of  150  cases  of  
prostatic  lesions,  histopathological  analysis,  the  role  of  basal  cell  markers  
[IHC]  are  studied  during  the period from  Jan 2010  to  March 2012 .   The  
following  are  the  salient  observation  noted  in  this  study. 
1.     Prostatic  specimens  constituted  1.42%  total  number  of  surgical  
specimens  received  during the  same  period. 
2. Out  of  150  cases  studied,  the  commonest  pathology  encountered  was  
benign  lesion  constituting 86.67%  and  malignant  lesions  were 13.33% .    
3. Among  the  benign  lesions,  benign  nodular  hyperplasia  is  the  most  
commonly  observed  pathology  of  prostate. 
4. The  age  incidence  of  nodular  hyperplasia  is  between  4th  and  8th  
decade. 
5. The  incidence  of  LGPIN  is 2.31%    and   HGPIN  is 6.92%  in  TURP   
specimen  of  nodular  hyperplasia. 
6. Among  the 130   cases  of  benign lesion,90 cases  were  diagnosed  as  
nodular  hyperplasia,  8 cases    with  prostatitis.  Basal  cell  hyperplasia  in  
8    cases,  squamous  metaplasia  in 2 cases and atrophy in 7 cases.     
 
 
7. Among  the  malignant  neoplasm  of  the  prostate,  adenocarcinoma  is  
the  commonest 
8. Incidence  of  carcinoma  was 13.33%   and  peak  age  group  affected  was   
between 60-69 yrs.     
9. Gleason’s  score  of 5-7  was  seen  in  85%    of  the  cases.  Gleason  score  
of  8  and  10  was  seen  in  10%    of  cases. 
10. With  regard  to  IHC  studies  12  cases  were  selected  and  tested  with  
HMWCK  and  p63  and  comparative  study  was  done. 
11. It  is  found  that  p63    is  more  sensitive  than  HMWCK  in  identifying  
basal  cells  according  to  our  study. 
                        
               In  summary,  we  found  that  immunohistochemical  p63  staining  
is  diagnostically  reliable  in  identifying  basal  cells  in  TURP  specimens  
and  compares  favourably  with  high  molecular  weight  cytokeratin  
staining. In TURP specimens  in  which  cautery  artifact can impair  the  
ability  to  detect  high  molecular  weight  cytokeratin , staining  for  p63  
appears  superior. In  addition,  p63  staining  which  shows  a  nuclear  
reaction  is  easy  to  interpret  than  HMWCK  which  shows  cytoplasmic  
reaction. 
 
 
 
 
 
 
APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         APPENDIX  -  I 
 
                                 HAEMATOXYLIN  AND  EOSIN  STAINING. 
PREPARATION  OF  SOLUTIONS: 
HARRIS  HAEMATOXYLIN 
Distilled  water  -  1000  ml 
Ammonium  alum  -  100  g 
Haematoxylin  -  5  g 
Absolute  ethyl  Alcohol  -  50  ml 
Mercuric  Oxide  -  2.5  g 
100  g  of  Ammonium  alum  dissolved  in  1000  ml  of  distilled  water  by  
heating  and  shaking  at  60°  C.  Add  solution  of  5  g  of  Haematoxylin  in  50  ml  
of  Ethylalcohol  and  bring  rapidly  to  boil.  When  it  begins  boil,  remove  from  
flame  and  acid  2.5  g  of  Mercuric  Oxide.  Mix  by  Swirling  gently.   
EOSIN  STAIN 
EOSIN Y  -  1  g 
Distilled  water  -  20  ml 
95%  Ethanol  -  80  ml 
Glacial  acetic  acid  -  0.2  ml 
 
 
Dissolve  1  g  Eosin  Y  in  20  ml  of  water  and  add  95%  ethanol  and  glacial  
acetic  acid. 
PROCEDURE: 
1. Dewax  the  sections  through  two  changes  of  Xylene  and  hydrate  the  
sections  through  descending  grades  of  alcohol  to  water. 
2.Stain  in  Harris’s  hematoxylin  for  5  minutes. 
3.Quickly  rinse  in  running  tap  water. 
4.Differentiate  in  1%  acid  alcohol  (2  -  3  quick  dips). 
5.Blue  the  sections  in  running  tap  water  for  10  minutes. 
6.Wash  in  running  tap  water  for  10  -  20  minutes. 
7.Stain  in  1%  Eosin  for  15  seconds  to  2  minutes. 
8.95%  alcohol  -  2  changes. 
9.Absolute  alcohol  -  atleast  2  changes. 
10.Xylene  - 2 changes. 
11.Mount  in  DPX  moutant. 
 
 
 
 
 
 
 
 
APPENDIX  -  II 
                                           IMMUNOHISTOCHEMISTRY 
Preparation  of  gelatin  coated  slide: 
          Chrome  alum  -  0.05  gm 
          Gelatin  -  0.3  gm 
          Distilled  water  -  100  ml 
First  chrome  alum  is  added  to  distilled  water  and  then  the  distilled  water  is  
heated  to  60° C  Gelatin  is  added  slowly  to  the  heated  distilled  water.  Glass  
slides  are then  dipped  in  this  solution  and  dried  overnight. 
Preparation  of  TRIS  BUFFERED  SALINE  (TBS):  0.005  M  TBS 
            Distilled  water  -  10  litres 
            Sodium  Chloride  -  80  g 
            TRIS  (Hydroxy  methylamine)  -  6.05  g 
            I M Hcl  -  44  ml 
Final  PH  is  adjusted  to  7.6  with  either  I M Hcl   or  0.2  M  Tris  solution. 
Preparation  of  CITRATE  buffer  solution  (antigen  retrieval  solution): 
Trisodium  Citrate  -  2.94  gms 
IN  Hcl  -  5  ml 
 
 
Distilled  water  -  1000  ml 
Final  PH  is  adjusted  to  6.0  with  IN  Hcl. 
Antigen  Retrieval: 
The  slides  are  placed  in  citrate  buffer  in  the  coplin  jar  and  capped.  The  jar  
is  then  heated  in  a  750  w  domestic  microwave  oven  for  15  minutes  (5  
minutes  in  low  power  (40)  5  minutes  in  medium  power  (60)  and  5  minutes  
in  full  power  (80)  pausing  only  to  top  up  the  fluid. 
Procedure  adopted  for  IHC: 
1.Dewax  the  sections  in  Xylene  (1/2  hour,  two  changes  and  bring  sections  
to distilled  water. 
2.Antigen  retrieval  using  TBS  by  microwave  oven  heating. 
3.Cool  to  room  temperature  in  running  tap  water  for  20  minutes. 
4.Bring  sections  to  TBS  for  5  minutes. 
5.Drain  and  wipe  off  excess  TBS  around  sections. 
6.Incubate  in  endogenous  peroxidase  blocking  reagent  for  15  -  20  minutes. 
7.Gently  wash  the  slides  in  TBS  for  5  minutes. 
8.Wipe  off  the  excess  fluid  and  incubate  in  power  block  reagent  for  15  -    
20  minutes. 
9.Wipe  the  excess  fluid  and  incubate  in  Primary  Antibody  for  60  minutes. 
 
 
  10.Repeat  steps  4  and  5. 
  11.Incubate  in  super  enhancer  for  30  minutes. 
  12.Repeat  steps  4  and  5. 
  13. Incubate  in  enzyme  labeled  polymer  secondary  antibody  (supersensitive  
poly  HRP)  for  30  minutes. 
 14.Repeat  steps  4  and  5. 
  15.Incubate  in  DAB  (Diamino  Benzidine)  substrate  solution  for  2  -  10  
minutes. 
(To  prepare  DAB  substrate,  add  1  ml  of  substrate  buffer,  1  drop  of  liquid  
DAB,  and  1  drop  of  substrate  DAB). 
  16.Wash  in  distilled  water,  counter  stain  with  Hematoxylin,  clear  in  Xylene  
and  mount  with  DPX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER  CHART 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
SL. 
NO. 
PATH 
NO. 
IP NO. AGE/ 
SEX 
CLINICAL 
DIAGNOSIS 
HP DIAGNOSIS BIOPSY 
SPECIMEN 
1 64/10 1058764 60/M BPH NODULAR 
HYPERPLASIA 
TURP 
2 72/10 1061005 65/M BPH NODULAR 
HYPERPLASIA 
TURP 
3 PP 84/10 - 73/M BPH NODULAR  
HYPERPLASIA 
TURP 
4 107/10 1060338 55M  
BPH 
NODULAR 
HYPERPLASIA 
TURP 
5 318/10 1065154 60/M CA 
PROSTATE 
PROSTATIC 
ADENOCARCINOMA 
TURP 
6 500/10 1065866 55/M CA 
PROSTATE 
 PROSTATIC 
ADENOCARCINOMA 
TURP 
7 676/10 1065181 80/M BPH NODULAR 
HYPERPLASIA 
TURP 
8 595/10 1069744 72/M BPH NODULAR 
HYPERPLASIA 
TURP 
9 862/10 1072749 67/M BPH NODULAR 
HYPERPLASIA 
TURP 
10 946/10 1071214 65/M BPH   NODULAR 
HYPERPLASIA WITH 
CHRONIC PROSTATITIS 
TURP 
11 1055/10 1073271 70/M BPH BENIGN PROSTATIC 
HYPERTROPHY WITH 
BASAL CELL 
HYPERPLASIA 
TURP 
12 1474/10 1076800 60/M BPH NODULAR 
HYPERPLASIA 
TURP 
13 1475/10 1075834 42/M BPH NODULAR 
HYPERPLASIA OF 
PROSTATE WITH 
CHRONIC PROSTATITIS 
TURP 
 
 
14 1574/10 1080994 65/M BPH NODULAR  
HYPERPLASIA 
TURP 
15 1778/10 1080751 65/M BPH NODULAR  
HYPERPLASIA  WITH 
FOCAL  PIN 
TURP 
16 1875/10 1083417 55/M BPH NODULAR 
HYPERPLASIA OF 
PROSTATE 
TURP 
17 1877/10 1083596 70/M BPH NODULAR 
HYPERPLASIA OF 
PROSTATE 
TURP 
18 2288/10 0322485 63/M BPH NODULAR  
HYPERPLASIA 
TURP 
19 2291/10 0322486 65/M BPH NODULAR  
HYPERPLASIA 
TURP 
20 2342/10 0322490 80/M BPH NODULAR  
HYPERPLASIA 
TURP 
21 2396/10 1085782 53/M BPH NODULAR  
HYPERPLASIA 
TURP 
22 2451/10 1088471 80/M BPH NODULAR  
HYPERPLASIA 
TURP 
23 2530/10 1091129 42/F BPH NODULAR  
HYPERPLASIA 
TURP 
24 2859/10 1084536 50/M BPH NODULAR  
HYPERPLASIA 
TURP 
25 2858/10 1090445 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
26 2979/10 1096307 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
27 3139/10 1096299 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
28 3228/10 1100278 79/M BPH NODULAR  
HYPERPLASIA   
TURP 
29 3308/10 109856 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
30 3497/10 1100264 70/M BPH NODULAR  
HYPERPLASIA 
TURP 
 
 
31 3902/10 1106534 60/M BPH  NODULAR 
HYPERPLASIA  WITH 
INCOMPLETE BASAL  
CELL HYPERPLASIA 
TURP 
32 4060/10 1201290 50/M BPH NODULAR 
HYPERPLASIA 
TURP 
33 4314/10 1202643 55/M BPH NODULAR  
HYPERPLASIA 
TURP 
34 4314/10 1202643 55/M BPH NODULAR 
HYPERPLASIA 
TURP 
35 4316/10 1203296 60/M BPH  NODULAR 
HYPERPLASIA  
TURP 
36 4443/10 1205816 62/M BPH NODULAR  
HYPERPLASIA 
TURP- 
37 311/11 1303111 50/M BPH NODULAR 
HYPERPLASIA   
TURP 
38 458/11 1303511 55/M BPH NODULAR 
HYPERPLASIA  
TURP 
39 557/11 1306100 62/M BPH NODULAR  
HYPERPLASIA 
TURP 
40 609/11 1306549 56/M BPH NODULAR 
HYPERPLASIA 
TURP 
41 889/11 1306549 56/M BPH NODULAR 
HYPERPLASIA WITH  
PROSTATITIS 
TURP 
42 1185/11 1311457 52/M CA 
PROSTATE  
PROSTATIC 
ADENOCARCINOMA  
TURP 
43 1186/11 1314107 70/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA OF 
PROSTATE 
TURP 
44 1254/11 1311557 60/M BPH BENIGN  PROSTATIC 
HYPERPLASIA 
TURP 
45 1573/11 1316922 80/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA 
TURP 
46 1571/11 1319294 70/M ?CA 
PROSTATE   
 
NODULAR 
HYPERPLASIA  WITH 
BCH 
TURP 
 
 
47 1575/11 1319092 55/M ?CA 
PROSTATE 
NODULAR 
HYPERPLASIA  WITH 
PROSTATITIS 
TURP 
48 1576/11 1319096 75/M CAPROSTAT
E 
NODULAR 
HYPERPLASIA  WITH 
BCH 
TURP 
49 1806/11 1319095 76/M BPH NODULAR 
HYPERPLASIA 
TURP 
50 1806/11 1319095 76/M BPH NODULAR 
HYPERPLASIA OF 
PROSTATE 
TURP 
51 1927/11 1319294 70/M BPH NODULAR  
HYPERPLASIA, 
CHRONIC PROSTATITIS 
TURP 
52 2144/11 1326208 58/M BPH NODULAR 
HYPERPLASIA ,BCH , 
CHRONIC  
PROSTATITIS 
TURP 
53 2281/11 1325578 65/M BPH NODULAR 
HYPERPLASIA 
TURP 
54 2306/11 1322765 70/M BPH NODULAR 
HYPERPLASIA ,PIN II 
CHANGES  
TURP 
55 2346/11 1297100 55/M CA 
PROSTATE 
PROSTATIC ADENO CA TRUCUT 
BIOPSY 
56 2405/11 1322767 60/M BPH NODULAR  
HYPERPLASIA ,PIN I-II 
CHANGES 
TURP 
57 2468/11 1324472 78/M BPH NODULAR 
HYPERPLASIA   
TURP 
58 2465/11 1328467 60/M BPH NODULAR 
HYPERPLASIA 
TURP 
59 2467/11 1327117 52/M BPH NODULAR 
HYPERPLASIA 
TURP 
60 2581/11 1461111 65/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA,PIN 
CHANGES 
TRUCUT 
BIOPSY 
 
 
61 2676/11 1333873 47/M CA 
PROSTATE 
ADENOCA PROSTATE TRUCUT 
BIOPSY 
62 2724/11 1331546 72/M BPH NODULAR 
HYPERPLASIA, PIN I 
CHANGES 
TURP 
63 2727/11 1331577 61/M BPH NODULAR 
HYPERPLASIA OF 
PROSTATE 
TURP 
64 2775/11 1331244 55 /M BPH NODULAR 
HYPERPLASIA WITH 
PIN II CHANGES 
TURP 
65 2813/11 1334592 63/M BPH NODULAR 
HYPERPLASIA  
TURP 
66 2814/11 1331954 58/M BPH NODULAR 
HYPERPLASIA  
TURP 
67 2954/11 1333515 62/M BPH NODULAR 
HYPERPLASIA        
TURP 
68 2955/11 1333870 50/M BPH NODULAR 
HYPERPLASIA 
TURP 
69 3036/11 1336998 56/M   CA 
PROSTATE 
ADENOCARCINOMA 
OF PROSTATE 
TRUCUT 
BIOPSY 
70 3209/11 1336485 62/M BPH PIN I-II ,NODULAR 
HYPERPLASIA OF 
PROSTATE 
TURP 
71 3210/11 1338508 65/M BPH NODULAR 
HYPERPLASIA, 
CHRONIC 
PROSTATITIS 
TURP 
72 3265/11 1338294 66/M BPH  NODULAR 
HYPERPLASIA 
TURP 
73 3371/11 1338893 58/M BPH NODULAR 
HYPERPLASIA, 
CHRONIC 
PROSTATITIS 
TURP 
74 3385/11 1339922 62/M BPH NODULAR 
HYPERPLASIA WITH 
PIN I 
TURP 
 
 
75 3524/11 1342583 58/M BPH NODULAR 
HYPERPLASIA OF 
PROSTATE 
TURP 
76 3527/11 1349815 66/M BPH NODULAR  
HYPERPLASIA  OF  
PROSTATE 
TURP 
77 3615/11 1338878 65/M BPH ADENOCA PROSTATE  TURP 
78 3748/11 1341764 60/M CA 
PROSTATE 
BENIGN PROSTATIC 
HYPERPLASIA 
TURP 
79 3800/11 1345504 55/M BPH NODULAR 
HYPERPLASIA 
TURP 
80 3801/11 1344382 60/M CA 
PROSTATE 
PROSTATIC 
HYPERPLASIA 
TURP 
81 3802/11 1344711 64/M BPH NODULAR 
HYPERPLASIA,  
PIN-2 CHANGES  
TURP 
82 3824/11 1343165 62/M BPH NODULAR 
HYPERPLASIA 
TURP 
83 3926/11 1342577 58/M BPH NODULAR 
HYPERPLASIA 
TURP 
84 3927/11 1346999 60/M BPH NODULAR 
HYPERPLASIA 
TURP 
85 3953/11 1348233 65/M CA 
PROSTATE 
ADENOCA PROSTATE  TRUCUT 
BIOPSY 
86 3954/11 1343674 65/M BPH PIN 2 TURP 
87 3952/11 1348644 60/M ?CA 
PROSTATE 
NODULAR 
HYPERPLASIA ,ACUTE 
PROSTATITIS 
TURP 
88 4014/11 1348466 66/M ?CA 
PROSTATE 
NODULAR 
HYPERPLASIA 
TURP 
89 4015/11 1348588 55/M BPH  NODULAR 
HYPERPLASIA,PIN 2 
CHANGES 
TURP 
90 4043/11 1395709 58/M BPH NODULAR 
HYPERPLASIA 
TURP 
91 4043/11 1395709 58/M BPH NODULAR 
HYPERPLASIA 
TURP 
 
 
92 4083/11 1351447 60/M CA 
PROSTATE 
PROSTATIC ADENO CA TRUCUT 
93 4084/11 1349568 80/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA 
TRUCUT 
94 4104/11 1347323 75/M BPH NODULAR 
HYPERPLASIA,PIN II 
CHANGES 
TURP 
95 4107/11 1351383 60/M CA 
PROSTATE 
 NODULAR  
HYPERPLASIA ,PIN 2 
CHANGES 
TRUCUT 
BIOPSY 
96 4108/11 1350467 70/M CA 
PROSTATE 
BASAL CELL 
HYPERPLASIA 
TRUCUT 
BIOPSY 
97 4109/11 1359402 70/M BPH NODULAR 
HYPERPLASIA OF 
PROSTATE 
TRUCUT 
BIOPSY 
98 4363/11 1353260 80/M BPH NODULAR 
HYPERPLASIA WITH 
ACUTE PROSTATITIS 
TURP 
99 4448/11 1354724 81/M CA 
PROSTATE 
PROSTATIC ADENOCA TRUCUT 
BIOPSY 
100 4576/11 1355973 60/M CA 
PROSTATE 
PROSTATIC ADENOCA TRUCUT 
BIOPSY 
101 4604/11 1355477 70/M BPH BENIGN PROSTATIC 
HYPERPLASIA WITH 
PIN I CHANGES 
TURP 
102 4607/11 1352733 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
103 4663/11 1351091 65/M BPH NODULAR  
HYPERPLASIA 
TURP 
104 4669/11 1352729 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
105 4753/11 1349969 70/M BPH NODULAR 
HYPERPLASIA  
TURP 
106 4755/11 1358402 50/M BPH NODULAR  
HYPERPLASIA 
TURP 
107 4811/11 1359012 52/M BPH NODULAR  
HYPERPLASIA 
TURP 
 
 
108 4833/11 1354390 65/M BPH NODULAR  
HYPERPLASIA 
TURP 
109 4838/11 1359167 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
110 5/12 1358710 80/M CA 
PROSTATE 
PROSTATIC ADENO CA TRUCUT 
BIOPSY 
111 7/12 1359269 63/M CA 
PROSTATE 
PROSTATIC ADENO CA TRUCUT  
BIOPSY 
112 8/12 386011 70/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA PIN I-II 
CHANGES 
TRUCUT  
BIOPSY 
113 9/12 1358721 50/M BPH NODULAR  
HYPERPLASIA  
TURP 
114 53/12 1359043 62/M BPH NODULAR    
HYPERPLASIA 
TURP 
115 58/12 1357633 75/M BPH PROSTATIC ADENOCA TURP 
116 116/12 1354819 70/M BPH NODULAR 
HYPERPLASIA WITH 
CHRONIC PROSTATITIS 
TURP 
117 174/12 130732 75/M BPH NODULAR  
HYPERPLASIA  WITH  
CHRONIC  PROSTATITIS 
TURP 
118 179/12 1358993 58/M BPH NODULAR 
HYPERPLASIA   
TURP 
119 181/12 1359031 65/M BPH PROSTATIC ADENOCA  TURP 
120 180/12 1359302 60/M BPH NODULAR 
HYPERPLASIA 
TURP 
121 202/12 1360702 58/M BPH NODULAR 
HYPERPLASIA   
TURP 
122 244/12 1361976 60/M BPH NODULAR 
HYPERPLASIA   
TURP 
123 248/12 1363441 65/M BPH NODULAR  
HYPERPLASIA   
TURP 
124 523/12 1362955 65/M BPH PROSTATIC ADENO CA TRUCUT 
BIOPSY 
125 530/12 1365655 62/M BPH NODULAR 
HYPERPLASIA   
TURP 
 
 
126 527/12 1362955 65/M CA 
PROSTATE 
PROSTATIC ADENOCA TRUCUT 
BIOPSY 
127 606/12 1365181 60/M BPH  NODULAR 
HYPERPLASIA   
TURP 
128 767/12 136545 40/M BPH NODULAR 
HYPERPLASIA  
TURP 
129 812/12 1371050 66/M BPH PROSTATIC ADENO CA TURP 
130 813/12 1370458 61/M BPH  NODULAR 
HYPERPLASIA  
TURP 
131 814/12 1362812 74/M BPH BENIGN NODULAR 
HYPERPLASIA , 
CHRONIC PROSTATIS 
TURP 
132 958/12 1368033 70/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA WITH 
PIN CHANGES 
TRUCUT 
BIOPSY 
133 1026/12 1372983 61/M BPH NODULAR 
HYPERPLASIA  WITH 
SQUAMOUS 
METAPLASIA 
TURP 
134 1114/12 1372826 56/M BPH NODULAR 
HYPERPLASIA 
TURP 
135 1162/12 1374590 56/M BPH BENIGN NODULAR 
HYPERPLASIA WITH 
CHRONIC 
PROSTATITIS 
TURP 
136 1208/12 1372988 68/M BPH NODULAR  
HYPERPLASIA 
TURP 
137 1209/12 1373175 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
138 1211/12 1371929 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
139 1332/12 1375846 60/M BPH NODULAR  
HYPERPLASIA 
TURP 
140 1359/12 1374270 59/M BPH NODULAR 
HYPERPLASIA 
TURP 
141 1595/12 1381142 65/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA 
TURP 
 
 
142 1597/12 1381145 45/M BPH NODULAR  
HYPERPLASIA 
TURP 
143 1640/12 1382356 61/M BPH NODULAR  
HYPERPLASIA 
TURP 
144 1642/12 1382358 65/M BPH NODULAR  
HYPERPLASIA 
TURP 
145 1760/12 1384570 60/M BPH NODULAR 
HYPERPLASIA   
TURP 
146 1762/12 1384573 65/M CA 
PROSTATE 
NODULAR  
HYPERPLASIA 
TRUCUT 
BIOPSY 
147 1874/12 1396234 83/M CA 
PROSTATE 
ADENO CARCINOMA 
PROSTATE 
TRUCUT  
BIOPSY 
148 1875/12 1396235 65/M CA 
PROSTATE 
NODULAR 
HYPERPLASIA WITH 
BASAL CELL 
HYPERPLASIA 
TURP 
149 2063/12 1401214 60/M BPH NODULAR 
HYPERPLASIA   
TURP 
150 1994/12 1401193 64/M BPH NODULAR  
HYPERPLASIA 
TURP 
 
BPH -  BENIGN  PROSTATIC  HYPERPLASIA 
BCH – BASAL  
PIN - PROSTATIC INTRAEPITHELIAL NEOPLASIA 
CA-CARCINOMA. 
TURP – TRANS URETHRAL RESECTION OF PROSTATE 
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                                                  ABSTRACT 
                          
                 Prostatic  nodular  hyperplasia  and  adenocarcinoma  are  common  
diseases  that  account  for  considerable  morbidity  and  mortality  in  the  aging  
population.  Interpretation  of  prostatic  biopsies  has  been  and  continues  to  
be  a  challenge  to  the  pathologist.  In  such  situations,  immunohistochemical  
detection  of  basal  cells  is  widely  used  to  help  in  the diagnosis  or  exclusion  
of  prostatic  carcinoma. We  analysed  150  cases  of  prostatic  lesions  
histopathologically,out  of  which  130  cases  were  benign  lesions  and  20  were  
malignant.  Among  premalignant  lesions  12  cases  were  found  along  with  
nodular  hyperplasia  &3  cases  were  found  along  with  carcinoma.  We  
selected  12  cases  for  IHC  studies  and  studied  the  role  of  p63  verses  
HMWCK  in  distinguishing  prostatic  carcinoma  from  its  benign  lesions  and  its  
precursors. We  found  that  immunohistochemical  p63  staining  is  diagnostically  
reliable  in  identifying  basal  cells  in  TURP  specimens  and  compares  
favourably  with  HMWCK.  In  addition,  p63  staining  which  shows  a  nuclear  
reaction  is  easy  to  interpret  than  HMWCK  which  shows  cytoplasmic  
reaction. 
   
